<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8703677</article-id><article-id pub-id-type="pmcid-ver">PMC8703677.1</article-id><article-id pub-id-type="pmcaid">8703677</article-id><article-id pub-id-type="pmcaiid">8703677</article-id><article-id pub-id-type="pmid">34960149</article-id><article-id pub-id-type="doi">10.3390/vaccines9121403</article-id><article-id pub-id-type="publisher-id">vaccines-09-01403</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>A Review of UK-Registered and Candidate Vaccines for Bovine Respiratory Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Lemon</surname><given-names initials="JL">Joanne L.</given-names></name><xref rid="af1-vaccines-09-01403" ref-type="aff">1</xref><xref rid="c1-vaccines-09-01403" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McMenamy</surname><given-names initials="MJ">Michael J.</given-names></name><xref rid="af2-vaccines-09-01403" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Tripp</surname><given-names initials="RA">Ralph A.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-09-01403"><label>1</label>Sustainable Agri-Food and Sciences Division, Agri-Food and Bioscience Institute, Newforge Lane, Belfast BT9 5PX, UK</aff><aff id="af2-vaccines-09-01403"><label>2</label>Veterinary Sciences Division, Agri-Food and Bioscience Institute, Stormont, Belfast BT4 3SD, UK; <email>michael.mcmenamy@afbini.gov.uk</email></aff><author-notes><corresp id="c1-vaccines-09-01403"><label>*</label>Correspondence: <email>joanne.lemon@afbini.gov.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>11</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2021</year></pub-date><volume>9</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">396540</issue-id><elocation-id>1403</elocation-id><history><date date-type="received"><day>26</day><month>8</month><year>2021</year></date><date date-type="accepted"><day>22</day><month>11</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>11</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>25</day><month>12</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-31 13:25:23.830"><day>31</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-09-01403.pdf"/><abstract><p>Vaccination is widely regarded as a cornerstone in animal or herd health and infectious disease management. Nineteen vaccines against the major pathogens implicated in bovine respiratory disease are registered for use in the UK by the Veterinary Medicines Directorate (VMD). However, despite annual prophylactic vaccination, bovine respiratory disease is still conservatively estimated to cost the UK economy approximately &#163;80 million per annum. This review examines the vaccine types available, discusses the surrounding literature and scientific rationale of the limitations and assesses the potential of novel vaccine technologies.</p></abstract><kwd-group><kwd>vaccination</kwd><kwd>pathogens</kwd><kwd>efficacy</kwd><kwd>non-microbial risks</kwd><kwd>candidate</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-09-01403"><title>1. Introduction</title><p>Bovine respiratory disease complex (BRDC) is the principal cause of mortality in calves from 1&#8211;24 months of age across the world [<xref rid="B1-vaccines-09-01403" ref-type="bibr">1</xref>]. It has a significant impact on the global economy&#8212;the National Animal Disease Information Service (NADIS) estimates a cost to the UK alone of &#163;80 million per annum, with over 1.9 million animals affected [<xref rid="B2-vaccines-09-01403" ref-type="bibr">2</xref>]. In the US this figure is estimated to be around $54.1 million, with over 1/5th of cattle affected in any given year [<xref rid="B3-vaccines-09-01403" ref-type="bibr">3</xref>]. Additionally, BRDC is a recurring problem in many other parts of the world [<xref rid="B4-vaccines-09-01403" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-09-01403" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-09-01403" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-09-01403" ref-type="bibr">7</xref>] and is widespread across Europe [<xref rid="B8-vaccines-09-01403" ref-type="bibr">8</xref>,<xref rid="B9-vaccines-09-01403" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-09-01403" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-09-01403" ref-type="bibr">11</xref>]. </p><p>Costs involved can be both direct and incidental&#8212;from mortality, weight loss or carcass blemish and subsequent reduced market price to additional labour expenditure, housing modifications and prophylactic or therapeutic treatments [<xref rid="B3-vaccines-09-01403" ref-type="bibr">3</xref>,<xref rid="B12-vaccines-09-01403" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-09-01403" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-09-01403" ref-type="bibr">14</xref>]. Respiratory disease can occur throughout the year, however BRDC is largely seasonal in nature with outbreaks occurring within one month of housing in autumn or early winter, thus vaccination usually occurs in late summer [<xref rid="B15-vaccines-09-01403" ref-type="bibr">15</xref>].</p><p>Although the focus of this paper is the bovine respiratory disease complex, multiple coinfections or superinfections from numerous respiratory pathogens lead to similarly critical complexes in many other species, such as in pigs [<xref rid="B16-vaccines-09-01403" ref-type="bibr">16</xref>] sheep [<xref rid="B17-vaccines-09-01403" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-09-01403" ref-type="bibr">18</xref>] dogs (also known as kennel cough) [<xref rid="B19-vaccines-09-01403" ref-type="bibr">19</xref>] and cats [<xref rid="B20-vaccines-09-01403" ref-type="bibr">20</xref>] and follows the same disease course. Initially, the immunosupression arising from stressors and bovine viral diarrhoea virus (BVDV) infection increases vulnerability and thus the likelihood of viral infection. Viral infection has a dual effect on disease progression&#8212;first, there is direct damage to the airway epithelial layer and mucociliary escalator, thereby increasing susceptibility to secondary bacterial infection; secondly, the immunosuppressive nature of viral infection can lead to a decrease in the potency of immune responses, thereby potentially increasing opportunity for bacterial pathogens to be inhaled deeply into the lungs, causing lower respiratory tract (LRT) disease [<xref rid="B21-vaccines-09-01403" ref-type="bibr">21</xref>,<xref rid="B22-vaccines-09-01403" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-09-01403" ref-type="bibr">23</xref>]. Consequently, immunity is further suppressed, potentially aiding invasion from opportunistic non-commensal bacteria [<xref rid="B16-vaccines-09-01403" ref-type="bibr">16</xref>,<xref rid="B24-vaccines-09-01403" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-09-01403" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-09-01403" ref-type="bibr">26</xref>]. This results in bovine respiratory disease which presents as calf pneumonia. This concludes in either calf death or reduced growth after recovery. </p><p>Viral and bacterial microorganisms are the aetiological agents instigating BRD. Alongside, several non-microbial aspects have been identified as potential risk factors contributing to the risk of incidence of respiratory disease, discussed below. BRD is a multifaceted complex making it difficult to establish the exact contribution of each potential risk factor in decreasing resistance. However, all contributory risk factors act to elevate stress levels, reducing immunity and thus increase the susceptibility of cattle, particularly neonates [<xref rid="B27-vaccines-09-01403" ref-type="bibr">27</xref>]. Suitable alleviating mechanisms and infrastructures can reduce the severity and frequency of incidence of BRD: </p><p>(1) <italic toggle="yes">Housing</italic>: Housing, more specifically ventilation and stocking density, is often cited as the largest non-microbial risk factor for the development of BRD in 0&#8211;3 month old calves [<xref rid="B28-vaccines-09-01403" ref-type="bibr">28</xref>].</p><p>(2) <italic toggle="yes">Transport</italic>: There is a strong link between transport and BRDC-related morbidity [<xref rid="B29-vaccines-09-01403" ref-type="bibr">29</xref>]. In terms of both distance and method, transport is acknowledged as being a major stressor for cattle and calves are at the highest risk of developing respiratory disease just after shipment [<xref rid="B30-vaccines-09-01403" ref-type="bibr">30</xref>]. Often BRDC is referred to as &#8216;shipping disease&#8217; for this reason.</p><p>(3) <italic toggle="yes">Weather</italic>: Sudden and extreme temperature changes may have more of an impact on the risk of bovine respiratory disease developing than continually high or low temperatures [<xref rid="B30-vaccines-09-01403" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-09-01403" ref-type="bibr">31</xref>]. However, evidence of this is inconsistent [<xref rid="B32-vaccines-09-01403" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-09-01403" ref-type="bibr">33</xref>].</p><p>(4) <italic toggle="yes">Farm management</italic>: Many farm management and animal husbandry practices increase the risk of bovine respiratory disease developing including pre-movement activities (dehorning, castration, weaning), comingling, vaccination status and intensity of farming [<xref rid="B34-vaccines-09-01403" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-09-01403" ref-type="bibr">35</xref>].</p><p>(5) <italic toggle="yes">Genetics</italic>: Various studies report Charolais, Simmental, Blonde d&#8217;Aquitaine and Aberdeen Angus bulls to have greater resistance to BRDC than other breeds [<xref rid="B36-vaccines-09-01403" ref-type="bibr">36</xref>]. Other authors have suggested that calves intended for use in the beef industry have a lower risk of developing BRD than those in the dairy industry, thought to be due to a greater microflora diversity and additional pathogen exposure through cattle markets [<xref rid="B37-vaccines-09-01403" ref-type="bibr">37</xref>]. Several groups are now using molecular techniques to identify genetically vulnerable animals [<xref rid="B38-vaccines-09-01403" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-09-01403" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-09-01403" ref-type="bibr">40</xref>].</p><p>The main contributory pathogens are detailed in <xref rid="vaccines-09-01403-t001" ref-type="table">Table 1</xref>, below. More recently, metagenomic analysis highlighted the involvement of up to 21 viruses in including bovine nidovirus, bovine parvovirus 3 and bovine rhinitis viruses [<xref rid="B41-vaccines-09-01403" ref-type="bibr">41</xref>]. Additionally it suggests the involvement of Influenza D virus&#8212;a newly identified virus, first detected in the UK in the winter of 2017 [<xref rid="B42-vaccines-09-01403" ref-type="bibr">42</xref>]. Frequently, the bacterial and viral pathogens associated with BRDC interact synergistically to enhance disease [<xref rid="B43-vaccines-09-01403" ref-type="bibr">43</xref>,<xref rid="B44-vaccines-09-01403" ref-type="bibr">44</xref>,<xref rid="B45-vaccines-09-01403" ref-type="bibr">45</xref>] although often the exact mechanisms remain unclear.</p><p>Due to the complex aetiology surrounding the establishment of BRD it is difficult to ascertain the exact contribution of each pathogen. However, it is recognised that, on a global scale, seropositivity rates against all viral and bacterial associated with BRD are high and can sometimes be up to 100% Europe [<xref rid="B46-vaccines-09-01403" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-09-01403" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-09-01403" ref-type="bibr">48</xref>,<xref rid="B49-vaccines-09-01403" ref-type="bibr">49</xref>,<xref rid="B50-vaccines-09-01403" ref-type="bibr">50</xref>]. Clinical disease is frequently most severe in calves under 6 months of age, even in those with maternal antibodies [<xref rid="B51-vaccines-09-01403" ref-type="bibr">51</xref>].</p></sec><sec id="sec2-vaccines-09-01403"><title>2. Currently Available Vaccines against BRD</title><p>Nineteen vaccines against BRD are registered for use in the UK by the Veterinary Medicine Directorate [<xref rid="B52-vaccines-09-01403" ref-type="bibr">52</xref>]. Eight vaccines designed to target the viral and bacterial pathogens of BRD are multi or polyvalent and thus designed to target several pathogens in one vaccine, while 11 are monovalent (<xref rid="app1-vaccines-09-01403" ref-type="app">Appendix A</xref>; <xref rid="vaccines-09-01403-t0A1" ref-type="table">Table A1</xref> and <xref rid="vaccines-09-01403-t0A2" ref-type="table">Table A2</xref>). All vaccines available use whole virus, either modified live (attenuated) or inactivated, and all are administered by intramuscular, intranasal or subcutaneous routes. </p></sec><sec id="sec3-vaccines-09-01403"><title>3. Limitations of Currently Available BRD Vaccines</title><p>Ineffective vaccines, declining employment in the agricultural sector and increasing awareness of antimicrobial resistance has led policymakers to shift the focus onto the development of superior, more efficacious vaccines as a major contribution in reducing the pressure to intensify on the farming sector. Although many vaccines against BRD are currently available on the UK market, they have limitations. Only a few of the vaccines have been registered as suitable for use in pregnant or lactating cows and all require refrigeration. Additionally, all come with a strong recommendation for a booster to advance immunity and none have been tested for maternal antibody interference [<xref rid="B52-vaccines-09-01403" ref-type="bibr">52</xref>]. Only eleven of the vaccines registered for use in the UK are multivalent and only four have been tested and deemed suitable for use alongside other veterinary treatments, frequently with those of the same manufacturer. However, multiple pathogens are considered threats during the neonatal stage and so it is impractical and ineffectual to have monovalent or incompatible medicines. Vaccination against BRD presents many challenges:</p><sec id="sec3dot1-vaccines-09-01403"><title>3.1. Age of Administration</title><p>A major challenge to the development of a successful vaccines for BRD is the age at which calves must be vaccinated [<xref rid="B53-vaccines-09-01403" ref-type="bibr">53</xref>]. Peak viral infection occurs upwards from 1 month so vaccination must take place in the first few weeks of life to allow immunity to develop [<xref rid="B54-vaccines-09-01403" ref-type="bibr">54</xref>,<xref rid="B55-vaccines-09-01403" ref-type="bibr">55</xref>]. However, evidence shows a calf&#8217;s immune system to be immature at this time, thought to be a carryover from the immunotolerant state induced during pregnancy [<xref rid="B53-vaccines-09-01403" ref-type="bibr">53</xref>,<xref rid="B56-vaccines-09-01403" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-09-01403" ref-type="bibr">57</xref>]. To compound this problem, several essential farm management practices (discussed earlier) occur during this period increasing corticosteroid levels [<xref rid="B30-vaccines-09-01403" ref-type="bibr">30</xref>] and essential maternally-derived antibodies (MDA) may interfere with the development of any vaccine-induced immunity [<xref rid="B54-vaccines-09-01403" ref-type="bibr">54</xref>,<xref rid="B58-vaccines-09-01403" ref-type="bibr">58</xref>].</p></sec><sec id="sec3dot2-vaccines-09-01403"><title>3.2. Route of Administration</title><p>The majority of currently approved vaccines against BRD are to be used parenterally (i.e., sub-cutaneously or intramuscularly) and these have been demonstrated as producing protective immune responses [<xref rid="B59-vaccines-09-01403" ref-type="bibr">59</xref>,<xref rid="B60-vaccines-09-01403" ref-type="bibr">60</xref>,<xref rid="B61-vaccines-09-01403" ref-type="bibr">61</xref>,<xref rid="B62-vaccines-09-01403" ref-type="bibr">62</xref>]. However, parenteral vaccines are invasive, require trained personnel for sterile administration and often cause a &#8216;depot effect&#8217; at the local site of injection; in cattle this can lead to carcass scarring and thus reduced price [<xref rid="B63-vaccines-09-01403" ref-type="bibr">63</xref>]. More recently, epicutaneous vaccination using skin patches, a non-invasive, needle-free delivery route, has been investigated in mice against RSV with encouraging results [<xref rid="B64-vaccines-09-01403" ref-type="bibr">64</xref>].</p><p>It has also been hypothesised that it might be more rational to vaccinate at the initial site of pathogen entry&#8212;intranasally&#8212;thereby potentially preventing infection at source. Many more intranasal vaccines are getting approved and coming onto the market. Intranasal vaccination induces more localised and protective mucosal immunity through activation of nasal-associated lymphoid tissues (NALT). Although mucosal immunity can also be generated as a consequence of vaginal, anal and oral inoculation, intranasal delivery is preferable due to its many advantages (discussed in context with disadvantages in <xref rid="vaccines-09-01403-t002" ref-type="table">Table 2</xref>). In support of this, a study by Ellis et al. showed that intranasal administration of BRSV vaccines intended for parenteral use did not reduce the protective efficacy of the vaccines [<xref rid="B65-vaccines-09-01403" ref-type="bibr">65</xref>]. Additionally, Rossi et al. [<xref rid="B66-vaccines-09-01403" ref-type="bibr">66</xref>] demonstrated strong bronchoalveolar cell-mediated and antibody responses after a single intranasal delivery of a multivalent BRSV, BHV-1 and BPIV-3 vaccine.</p></sec><sec id="sec3dot3-vaccines-09-01403"><title>3.3. Type of Vaccines Available:</title><sec id="sec3dot3dot1-vaccines-09-01403"><title>3.3.1. Modified-Live (MLV) Vaccines</title><p>Modified-live vaccines, also called attenuated vaccines, are those which employ live replicating whole pathogen that has been weakened in the laboratory. Attenuation of pathogenic strains can be obtained by modifying the molecular construction of the genome, using chemical mutagenesis, gene deletion or by extensive serial passaging in non-host cell culture or embryonated chick eggs. Chemical mutagenesis has also been coupled with low temperatures to develop a cold-adapted temperature-sensitive strain (ctss) of HRSV that can only replicate in the upper respiratory tract [<xref rid="B67-vaccines-09-01403" ref-type="bibr">67</xref>]. Only two diseases have been successfully eradicated across the globe&#8212;smallpox in humans [<xref rid="B68-vaccines-09-01403" ref-type="bibr">68</xref>] and rinderpest in cattle [<xref rid="B69-vaccines-09-01403" ref-type="bibr">69</xref>,<xref rid="B70-vaccines-09-01403" ref-type="bibr">70</xref>]&#8212;and both have been achieved using modified-live vaccines, thus illustrating their significant contribution to human and veterinary health. </p></sec><sec id="sec3dot3dot2-vaccines-09-01403"><title>3.3.2. Inactivated Vaccines</title><p>Inactivated vaccines, also known as killed vaccines, are those which do not contain any live replicating pathogenic material and cannot cause disease. For this reason they have a superior safety profile to their live counterparts [<xref rid="B71-vaccines-09-01403" ref-type="bibr">71</xref>] and are considered suitable for use in pregnant or lactating animals. The pathogenic agents are destroyed by heat, chemicals or radiation. Furthermore, inactivated vaccines do not require refrigeration and can be lyophilised for transport purposes [<xref rid="B72-vaccines-09-01403" ref-type="bibr">72</xref>].</p></sec><sec id="sec3dot3dot3-vaccines-09-01403"><title>3.3.3. Immunogenicity of Modified-Live and Inactivated Vaccines</title><p>As attenuated vaccines broadly mimic the immune response garnered from a natural infection, they are universally recognised for producing stronger, longer lasting and more robust immune responses for many pathogens [<xref rid="B72-vaccines-09-01403" ref-type="bibr">72</xref>,<xref rid="B73-vaccines-09-01403" ref-type="bibr">73</xref>,<xref rid="B74-vaccines-09-01403" ref-type="bibr">74</xref>,<xref rid="B75-vaccines-09-01403" ref-type="bibr">75</xref>]. Furthermore, it is surmised that modified-live vaccines can initiate cellular responses in a way that inactivated vaccines are not reported as doing [<xref rid="B76-vaccines-09-01403" ref-type="bibr">76</xref>,<xref rid="B77-vaccines-09-01403" ref-type="bibr">77</xref>]. Several studies report the benefits of using modified-live vaccines in calves [<xref rid="B78-vaccines-09-01403" ref-type="bibr">78</xref>,<xref rid="B79-vaccines-09-01403" ref-type="bibr">79</xref>,<xref rid="B80-vaccines-09-01403" ref-type="bibr">80</xref>,<xref rid="B81-vaccines-09-01403" ref-type="bibr">81</xref>]. However, several studies now indicate that evidence on this is conflicting [<xref rid="B81-vaccines-09-01403" ref-type="bibr">81</xref>,<xref rid="B82-vaccines-09-01403" ref-type="bibr">82</xref>] and even if this were conclusive, often the immunogenicity advantages gained from MLV are offset by the increased safety risks posed, particularly in neonates. </p><p>Conversely, the immune response garnered from using inactivated vaccines is considered by some as inadequate with suggestions that inactivated vaccines can effectively prime CD4+ T cells but encourage eosinophila [<xref rid="B83-vaccines-09-01403" ref-type="bibr">83</xref>] and others providing evidence that IFN&#947; expression is reduced [<xref rid="B84-vaccines-09-01403" ref-type="bibr">84</xref>]. A further study demonstrated a link between maternal vaccination for BVDV using inactivated vaccines and neonatal pancytopenia&#8212;a fatal autoimmune disease contracted from ingesting colostrum [<xref rid="B85-vaccines-09-01403" ref-type="bibr">85</xref>]. Further, although antibody titres can be high these are often found to be non-neutralising [<xref rid="B86-vaccines-09-01403" ref-type="bibr">86</xref>]. However, again, in contrast, several studies observed that using inactivated vaccines generated protection and they are at least as efficacious as using modified-live virus [<xref rid="B83-vaccines-09-01403" ref-type="bibr">83</xref>,<xref rid="B87-vaccines-09-01403" ref-type="bibr">87</xref>].</p></sec><sec id="sec3dot3dot4-vaccines-09-01403"><title>3.3.4. Vaccine-Enhanced Disease</title><p>Of particular note for BRSV is the observation that vaccination could actually augment disease. This was first noted in 1967 after a failed vaccine trail using a formalin-inactivated RSV (FI-RSV) vaccine against HRSV [<xref rid="B88-vaccines-09-01403" ref-type="bibr">88</xref>] which led to investigations in cattle where a similar pathology was reported [<xref rid="B89-vaccines-09-01403" ref-type="bibr">89</xref>,<xref rid="B90-vaccines-09-01403" ref-type="bibr">90</xref>]. In this study, one group was vaccinated with a FI-BRSV vaccine while the other was sham-vaccinated. Both groups were challenged with live BRSV post-vaccination. No significant difference in gross lung lesions and in lung function was noted between the two groups, indicating the failure of the vaccine to provide any protective immunity. Further, although two groups were challenged with the same amount of BRSV, the sham vaccinated cohort demonstrated lower mean clinical scores [<xref rid="B90-vaccines-09-01403" ref-type="bibr">90</xref>] indicating disease exacerbation arising from vaccination. High titres of non-neutralising antibodies have also been observed, which can be associated with a high IgE titres and an allergic, inflammatory Th2-type response [<xref rid="B91-vaccines-09-01403" ref-type="bibr">91</xref>] and it is hypothesised that disease escalation is attributed to FI-RSV generation of low affinity antibodies [<xref rid="B92-vaccines-09-01403" ref-type="bibr">92</xref>] targeted at non-protective epitopes. Consequently, apprehension surrounds trials employing inactivated vaccines and scientists are cautious about developing candidate vaccines using inactivated antigen. Although antibody titres generated from vaccination are not always correlated with reduced disease, vaccination against any other pathogen implicated in BRD does not appear to have had such a detrimental effect [<xref rid="B30-vaccines-09-01403" ref-type="bibr">30</xref>].</p></sec></sec><sec id="sec3dot4-vaccines-09-01403"><title>3.4. Storage Conditions</title><p>Incorrect vaccine storage is frequently cited as a main reason for vaccine failure [<xref rid="B93-vaccines-09-01403" ref-type="bibr">93</xref>]. Correct storage conditions are essential for conserving the three-dimensional structure of antigens, and thus essential for vaccines to retain their potency [<xref rid="B94-vaccines-09-01403" ref-type="bibr">94</xref>]. However, reliable vaccine storage is often not controlled for in a field setting. Vaccines which could potentially remain immunogenic outside of the cold chain (i.e., not refrigerated) would be greatly beneficial to remote regions, vast farms or areas lacking sufficient infrastructure [<xref rid="B95-vaccines-09-01403" ref-type="bibr">95</xref>]. Recently a candidate nanoparticle RSV vaccine derived from an Sf9 insect cell line has been trialled showing that, once re-suspended, the vaccine can remain stable for &lt; 60 days [<xref rid="B96-vaccines-09-01403" ref-type="bibr">96</xref>]. In further support of this, another group demonstrated that dry ice storage for up to 30 days did not detriment stability for a vaccine against East Coast fever&#8212;a tick-borne disease of cattle in Eastern and Central Africa with high mortality rates [<xref rid="B97-vaccines-09-01403" ref-type="bibr">97</xref>]. More recently a study into vaccines for tuberculosis showed that desiccation of liquid vaccine antigen increased thermostability outside of the cold-chain and produced a vaccine antigen more adaptable for mucosal use [<xref rid="B98-vaccines-09-01403" ref-type="bibr">98</xref>].</p></sec></sec><sec id="sec4-vaccines-09-01403"><title>4. Practical Considerations for Vaccine Development</title><sec id="sec4dot1-vaccines-09-01403"><title>4.1. Antimicrobial Medicines</title><p>Metaphylaxis is a commonly employed tactic within farming, primarily utilised against mastitis in cattle, and dihydrostreptomycin, marbofloxacin or oxytetracycline are the most frequently detected antibiotics used in cattle [<xref rid="B99-vaccines-09-01403" ref-type="bibr">99</xref>]. Prophylactic treatment of calves with ceftiofur, rather than after the appearance of clinical signs was shown to reduce the incidence of BRD [<xref rid="B100-vaccines-09-01403" ref-type="bibr">100</xref>] further supporting this approach. However, this heavy reliance on antibiotics aggravated by the combination of agricultural intensification alongside ineffective vaccines has resulted in production systems coming under scrutiny as a source of escalating antimicrobial resistance. Globally, antimicrobial consumption in animal production is expected to increase by almost 70% by 2030 [<xref rid="B101-vaccines-09-01403" ref-type="bibr">101</xref>] despite comprehensive UK government efforts to curtail usage [<xref rid="B102-vaccines-09-01403" ref-type="bibr">102</xref>]. </p></sec><sec id="sec4dot2-vaccines-09-01403"><title>4.2. EU Regulations</title><p>Regulatory requirements for registering a veterinary vaccine within the EU are less stringent than those necessary to register a human vaccine; a process which is regulated by the Veterinary Medicines Directorate [<xref rid="B103-vaccines-09-01403" ref-type="bibr">103</xref>,<xref rid="B104-vaccines-09-01403" ref-type="bibr">104</xref>]. The legislative requirements are laid down in 2009/9/EC and/or by the World Organisation for Animal Health (OIE). Vaccine development is geared towards reducing animal use, with current investigations into in vitro potency assays [<xref rid="B105-vaccines-09-01403" ref-type="bibr">105</xref>] and <italic toggle="yes">in silico</italic> systems vaccinology [<xref rid="B106-vaccines-09-01403" ref-type="bibr">106</xref>].</p><p>Council directive 81/852/EEC and the European Pharmacopoeia further detail requirements, stating that results from laboratory efficacy trials should be supplemented with data from field efficacy trials [<xref rid="B107-vaccines-09-01403" ref-type="bibr">107</xref>]. However, when laboratory efficacy cannot be supported by field trials, in vitro data alone may be acceptable; this can particularly relevant for diseases which lack suitable experimental infection models (i.e., BRSV), with diseases that are caused by more than one aetiological agent or in certain diseases where environmental factors play a major role in disease development. The development of BRDC can be applied to any of these criteria [<xref rid="B108-vaccines-09-01403" ref-type="bibr">108</xref>]. Only two parameters need to be measured: clinical picture (mortality, morbidity, lesions, weigh) and the serological response, but evidence shows cell-mediated immunity to play an important role against bovine respiratory disease [<xref rid="B109-vaccines-09-01403" ref-type="bibr">109</xref>,<xref rid="B110-vaccines-09-01403" ref-type="bibr">110</xref>].</p></sec><sec id="sec4dot3-vaccines-09-01403"><title>4.3. Veterinary Adjuvants</title><p>Vaccines which are poorly immunogenic often require an additional stimulant as a component to augment efficacy. These can potentially reduce vaccine antigen loads or administration frequency [<xref rid="B111-vaccines-09-01403" ref-type="bibr">111</xref>] thus reducing production costs. Removal of the pathogenic fragments of BRSV to leave only purified antigens (i.e., a sub-unit vaccine) will increase the safety profile of the vaccine, increasing the tolerability. However, this can also lead to a reduction in the immunogenicity and the vaccine-induced immune response generated [<xref rid="B112-vaccines-09-01403" ref-type="bibr">112</xref>]. This balance between immunogenicity and safety is represented in <xref rid="vaccines-09-01403-f001" ref-type="fig">Figure 1</xref>. Unlike human medicine, several adjuvants are registered for use in animal vaccines and all currently available vaccines employ aluminium compounds or variants. Despite its potent induction of cell-mediated immunity, the use of Complete or Incomplete Freund&#8217;s Adjuvant (CFA/IFA) is strictly controlled in veterinary vaccines due to toxicity and the induction of painful side effects [<xref rid="B113-vaccines-09-01403" ref-type="bibr">113</xref>,<xref rid="B114-vaccines-09-01403" ref-type="bibr">114</xref>]. Montanide is emerging as a novel veterinary adjuvant suitable for use in cattle due to the higher lymphoproliferative and antibody responses observed in vaccines in which it is incorporated [<xref rid="B115-vaccines-09-01403" ref-type="bibr">115</xref>,<xref rid="B116-vaccines-09-01403" ref-type="bibr">116</xref>]. The area of research on adjuvants is expanding quickly and other adjuvants under investigation for use in cattle vaccines include IL-18 [<xref rid="B117-vaccines-09-01403" ref-type="bibr">117</xref>] poly(diaminosulfide) nanoparticles [<xref rid="B118-vaccines-09-01403" ref-type="bibr">118</xref>] and bovine IL17A [<xref rid="B119-vaccines-09-01403" ref-type="bibr">119</xref>].</p></sec><sec id="sec4dot4-vaccines-09-01403"><title>4.4. Vaccination Regimes</title><p>Current vaccination regimes rely on a prime/boost regimen to obtain the greatest vaccine-induced immune response [<xref rid="B120-vaccines-09-01403" ref-type="bibr">120</xref>] and traditionally, boosting occurred with a homologous vaccine. Hill et al. demonstrated that intranasal vaccination of 3&#8211;6 week old calves using a modified-live BHV-1 vaccine followed by a booster with the same vaccine produced significantly higher IgA titres, reduced viral shedding and resulted in the least weight loss than a second vaccination with a heterologous (sub-cutaneous) vaccine [<xref rid="B121-vaccines-09-01403" ref-type="bibr">121</xref>]. However, other studies suggest that boosting with a heterologous vaccine can have a more beneficial effect as different arms of the immune system can be induced [<xref rid="B122-vaccines-09-01403" ref-type="bibr">122</xref>]. Important considerations are the vaccine antigen type [<xref rid="B123-vaccines-09-01403" ref-type="bibr">123</xref>] and the route of administration of the priming or boosting vaccine [<xref rid="B124-vaccines-09-01403" ref-type="bibr">124</xref>]. Due to the age at which BRD can develop and by extension the age at which vaccination is essential, induction of protective immunity following a single vaccine dose is highly desirable. Single dose vaccination has shown promising results in calves with MDA, using a modified live or recombinant BRSV vaccine administered intranasally or intramuscularly [<xref rid="B62-vaccines-09-01403" ref-type="bibr">62</xref>,<xref rid="B125-vaccines-09-01403" ref-type="bibr">125</xref>,<xref rid="B126-vaccines-09-01403" ref-type="bibr">126</xref>]. However, often little change is detected in virus neutralising antibodies (VNA) titres indicating that single inoculations may only be efficient at priming cell-mediated immunity [<xref rid="B127-vaccines-09-01403" ref-type="bibr">127</xref>]. </p></sec><sec id="sec4dot5-vaccines-09-01403"><title>4.5. Pre-Partum Vaccination</title><p>Pre-partum vaccination of a heifer or cow is a farm management strategy successfully used to provide immunity for neonates, primarily against enteric pathogens such as <italic toggle="yes">Escherichia coli (E. coli)</italic>, rotavirus or coronavirus [<xref rid="B128-vaccines-09-01403" ref-type="bibr">128</xref>,<xref rid="B129-vaccines-09-01403" ref-type="bibr">129</xref>]. Few report findings of maternal vaccination against BRD. However, Dudek et al. observed that maternal vaccination with a multivalent inactivated BRSV/BPIV-3/<italic toggle="yes">M. haemolytica</italic> vaccine, boosted colostrum immunoglobulin levels and led to increase in blood antibody titres in calves [<xref rid="B130-vaccines-09-01403" ref-type="bibr">130</xref>]. Additionally, it was reported that pre-partum vaccination positively impacted upon the antibody levels for BRSV, BHV-1, BVDV and BPIV-3. However, it was not considered significant enough to negate recommended neonatal vaccination schedules [<xref rid="B131-vaccines-09-01403" ref-type="bibr">131</xref>]. </p></sec></sec><sec id="sec5-vaccines-09-01403"><title>5. Candidate BRD Vaccines</title><p>Control strategies surrounding bovine respiratory disease concentrate on seasonal prophylactic antibiotic treatment and the administration of vaccines. Thus far these strategies have failed to prevent disease, with an estimated 1.9 million animals in the UK still affected by bovine respiratory disease annually. With increasing pressures on farms to intensify production alongside more rigid control on antibiotic use, research has focused on developing more efficacious, next generation vaccines.</p><sec id="sec5dot1-vaccines-09-01403"><title>5.1. Peptide Vaccines</title><p>There are currently no commercially available peptide vaccines for use in the veterinary field, despite the potential advantages in terms of ease of manufacture and flexibility. However, success has been reported for several candidate peptide vaccines and currently there is much interest in their use in human medicine, particularly against cancers [<xref rid="B132-vaccines-09-01403" ref-type="bibr">132</xref>], Human Immunodeficiency Virus [<xref rid="B133-vaccines-09-01403" ref-type="bibr">133</xref>] and diabetes [<xref rid="B134-vaccines-09-01403" ref-type="bibr">134</xref>]. In farm animals, Foot and Mouth Disease virus (FMDV) seems to command the largest share of research into peptide vaccines, in part due its status as a Specified Animal Pathogen Order (SAPO) level 4 infectious agent and of the economic impact of an outbreak [<xref rid="B135-vaccines-09-01403" ref-type="bibr">135</xref>,<xref rid="B136-vaccines-09-01403" ref-type="bibr">136</xref>]. Greenwood et al. describe using inert nanobeads conjugated with peptides from FMDV in sheep with higher antibody titres, increased TNF&#945;, IFN&#947;, IL-6 and greater T cell proliferation observed in immunised animals [<xref rid="B137-vaccines-09-01403" ref-type="bibr">137</xref>]. Vaccines based on epitopes of the FMDV surface protein VP1 have previously shown promise in swine [<xref rid="B138-vaccines-09-01403" ref-type="bibr">138</xref>] and Zhang et al. recently reported success with a peptide vaccine against FMDV detailing 100% protection after prime/boost vaccination and challenge in cattle [<xref rid="B139-vaccines-09-01403" ref-type="bibr">139</xref>]. Bastien et al. reported a reduction in pathological lesions, compared to unvaccinated controls, when calves were immunised with a peptide encompassing BRSV G<sub>174&#8211;187</sub> [<xref rid="B140-vaccines-09-01403" ref-type="bibr">140</xref>]. This had previously been shown to confer protection in mice [<xref rid="B141-vaccines-09-01403" ref-type="bibr">141</xref>]. Additionally, intraperitoneal immunisation of mice with a recombinant protein comprising HRSV G<sub>130&#8211;230</sub> coupled to streptococcal G protein protected mice from upper and lower respiratory tract infection [<xref rid="B142-vaccines-09-01403" ref-type="bibr">142</xref>]. However, despite the induction of high antibody titres in these studies, they were non-neutralising; a result repeated in a later study [<xref rid="B143-vaccines-09-01403" ref-type="bibr">143</xref>] implying that peptide vaccines provide protection by means other than a humoral response. </p></sec><sec id="sec5dot2-vaccines-09-01403"><title>5.2. Immune Stimulatory Complexes (ISCOMs)</title><p>ISCOMS are comprised of viral glycoproteins, cholesterol, phospholipids and non-toxic saponins from the bark of the Quillaja saponin tree (<italic toggle="yes">Quillaja saponaria</italic>). Tested using the surface antigens of HRSV and BRSV in guinea pigs [<xref rid="B144-vaccines-09-01403" ref-type="bibr">144</xref>] they have shown promise when used against BRSV in young calves with maternal antibodies [<xref rid="B145-vaccines-09-01403" ref-type="bibr">145</xref>]. Additionally, a bovine herpesvirus ISCOM vaccine demonstrated a high degree of immunogenicity when compared to the same BHV-1 proteins administered alone [<xref rid="B146-vaccines-09-01403" ref-type="bibr">146</xref>] and an ISCOM BVDV vaccine, which had previously been shown as protective in sheep, produced high serum neutralising titres when administered subcutaneously to calves [<xref rid="B147-vaccines-09-01403" ref-type="bibr">147</xref>]. </p></sec><sec id="sec5dot3-vaccines-09-01403"><title>5.3. Virus-Like Particles (VLP)</title><p>Virus-like particles (also known as pseudoviral particles) functionally and structurally resemble viruses and present viral antigens in a conformation more akin to a virion. As such, there is potential for lower antigenic doses to be used, reducing the cost of the vaccine&#8212;an important consideration in veterinary medicine [<xref rid="B148-vaccines-09-01403" ref-type="bibr">148</xref>]. As they do not contain genetic material they are non-infectious, non-replicating and safer than killed or attentuated vaccines. Although there is a lack of literature on VLPs for BRD, an early study demonstrated protection from clinical disease, significantly reduced leukopenia and led to the induction of cell-mediated and humoral immune responses when calves were immunised with a VLP containing BVDV 1b E2 glycoprotein antigens [<xref rid="B149-vaccines-09-01403" ref-type="bibr">149</xref>].</p></sec><sec id="sec5dot4-vaccines-09-01403"><title>5.4. Nanoparticle Vaccines</title><p>To protect peptides from proteolytic degradation by cytosolic aminopeptidases they require formulation with an additional component such as carrier proteins or nanoparticles. Nanoparticles can be relatively inexpensive to manufacture, biodegradable non-toxic and can augment the immunogenicity of subunit vaccines, leading to a potential decrease in antigen load or administration frequency. Further benefits include controlled antigen release, providing protection to antigen in the unfavourable conditions provided by the respiratory tract and the potential removal of the cold chain necessary for vaccine storage [<xref rid="B150-vaccines-09-01403" ref-type="bibr">150</xref>]. Circular nanoring structures derived from a recombinant N protein of HRSV were used as a novel candidate vaccine against BRSV in young calves, with encouraging results [<xref rid="B61-vaccines-09-01403" ref-type="bibr">61</xref>]. A PLGA nanoparticle vaccine for BPIV-3 demonstrated higher IgA and serum IgG responses than those generated from a commercial vaccine, although there was no detection of any cell-mediated immunity [<xref rid="B151-vaccines-09-01403" ref-type="bibr">151</xref>]. Vaccines based on nanoparticles have also been associated with a reduced need for therapeutic intervention [<xref rid="B152-vaccines-09-01403" ref-type="bibr">152</xref>] and a recent review highlighted the benefits gained from using natural nanoparticles in livestock vaccines from a One Health perspective [<xref rid="B153-vaccines-09-01403" ref-type="bibr">153</xref>]. </p></sec><sec id="sec5dot5-vaccines-09-01403"><title>5.5. DNA Vaccines</title><p>DNA vaccines evolved in the 1990s [<xref rid="B154-vaccines-09-01403" ref-type="bibr">154</xref>] and have since shown success against many veterinary pathogens [<xref rid="B155-vaccines-09-01403" ref-type="bibr">155</xref>,<xref rid="B156-vaccines-09-01403" ref-type="bibr">156</xref>,<xref rid="B157-vaccines-09-01403" ref-type="bibr">157</xref>]. The principal behind a DNA vaccine is that sequence encoding a protein of interest from the pathogen involved will be ligated into bacterial plasmid DNA, which is transfected in vitro and transferred to a host for in vivo transcription to subsequently induce an immune response [<xref rid="B158-vaccines-09-01403" ref-type="bibr">158</xref>]. Intradermal vaccination using a DNA vaccine which expressed the E2 glycoprotein of BVDV resulted in strong BVDV-specific T-cell proliferation and a significant rise in antibody titres [<xref rid="B159-vaccines-09-01403" ref-type="bibr">159</xref>]. An early study of an intramuscular DNA vaccine against Influenza A observed proficient stimulation of T and B cell responses, indicating an ability to cross-present antigen [<xref rid="B160-vaccines-09-01403" ref-type="bibr">160</xref>]. However, only some have proved promising for neonatal vaccination against BRD in young calves with maternally-derived antibodies [<xref rid="B161-vaccines-09-01403" ref-type="bibr">161</xref>]&#8212;many have only been tested in seronegative calves [<xref rid="B162-vaccines-09-01403" ref-type="bibr">162</xref>]. Furthermore, B cell responses have been observed as being slower to develop and ultimately lower in VNA titres than those from natural infection [<xref rid="B163-vaccines-09-01403" ref-type="bibr">163</xref>] or using a vectored vaccine [<xref rid="B163-vaccines-09-01403" ref-type="bibr">163</xref>]. More recently, a decrease in clinical disease and viral shedding in conjunction with an increased IFN&#436; and IgG response was noted after vaccination with a BHV-1 DNA vaccine [<xref rid="B164-vaccines-09-01403" ref-type="bibr">164</xref>]. With DNA vaccines, unlike protein-based vaccines, no mis-folding can occur. Additionally, when the production, storage, stability and safety advantages are taken into consideration alongside their proven ability to elicit both a cytotoxic and humoral response, it is clear this is an area worth researching more [<xref rid="B165-vaccines-09-01403" ref-type="bibr">165</xref>].</p></sec><sec id="sec5dot6-vaccines-09-01403"><title>5.6. Messenger RNA (mRNA) Vaccines</title><p>Messenger RNA vaccines are closely related to DNA vaccines with two major differences&#8212;firstly, mRNA does not need to be processed through the nucleus but instead is released directly into the cytoplasm for transcription and secondly, the need for effective transfection is negated [<xref rid="B166-vaccines-09-01403" ref-type="bibr">166</xref>]. Essentially, mRNA vaccines remove an additional molecular step needed by DNA vaccines to accelerate the generation of vaccine-induced immunity. The only approved mRNA vaccines on the market at present are against SARS-CoV-2 infection, responsible for the Covid 19 pandemic [<xref rid="B167-vaccines-09-01403" ref-type="bibr">167</xref>] and mRNA vaccines have continued to show promise in clinical trials for Zika virus [<xref rid="B168-vaccines-09-01403" ref-type="bibr">168</xref>], Influenza A [<xref rid="B169-vaccines-09-01403" ref-type="bibr">169</xref>] and rabies in humans [<xref rid="B170-vaccines-09-01403" ref-type="bibr">170</xref>]. The absence of published data relating to the use of mRNA vaccines in farm animals, and more specifically against the pathogens implicated in BRDC, serves to highlight the newness of this area of research. </p></sec><sec id="sec5dot7-vaccines-09-01403"><title>5.7. Viral Vectors</title><p>Viral vaccine vectors have been shown to capably induce robust cell mediated and humoral responses against <italic toggle="yes">Mannheimia haemolytica</italic> [<xref rid="B171-vaccines-09-01403" ref-type="bibr">171</xref>], BRSV [<xref rid="B163-vaccines-09-01403" ref-type="bibr">163</xref>], BHV-1 [<xref rid="B172-vaccines-09-01403" ref-type="bibr">172</xref>] and BVDV [<xref rid="B173-vaccines-09-01403" ref-type="bibr">173</xref>]. Unlike many other subunit vaccines often they do not require an adjuvant to boost immunity, instead relying on the inherent capability of a virus to enter and replicate in a cell. Poxvirus vectors show promise for multivalent vaccine use in cattle, due to the size of exogenous genes which can be accepted and they enjoy a superior safety profile due to their avian-restricted cytoplasmic replication. Vaccination with a recombinant modified Vaccinia virus Ankara (MVA) has shown much promise with BRSV [<xref rid="B174-vaccines-09-01403" ref-type="bibr">174</xref>] and its replication-deficiency makes it all the more suitable for use in the field. Importantly, potential disease-causing immunopathological reactions such as elevated IgE titres and eosinophil influx have not been observed in MVA vaccinated calves, post BRSV challenge [<xref rid="B175-vaccines-09-01403" ref-type="bibr">175</xref>]. Additionally, plant based vaccines are gaining prominence [<xref rid="B176-vaccines-09-01403" ref-type="bibr">176</xref>,<xref rid="B177-vaccines-09-01403" ref-type="bibr">177</xref>] and have shown efficacy when tested against BVDV [<xref rid="B178-vaccines-09-01403" ref-type="bibr">178</xref>]. Bovine respiratory pathogens are often used as vectors for other bovine respiratory pathogens&#8212;bovine herpesvirus-type 1 (BHV-1) has been successfully used against BRSV in calves reducing clinical signs, pneumonic lesions and viral loads despite low antibody titres [<xref rid="B179-vaccines-09-01403" ref-type="bibr">179</xref>] and a recombinant <italic toggle="yes">Pasteurella multocida</italic> vector has been shown to provide protection against <italic toggle="yes">Mannheimia haemolytica</italic> [<xref rid="B180-vaccines-09-01403" ref-type="bibr">180</xref>]. The majority of candidate vaccines using bovine respiratory pathogens as viral vectors focus on bovine RSV&#8212;as the model of BRSV disease in calves mirrors that of RSV infection in infants, this can be considered a reflection of the medical urgency for a human RSV vaccine. </p></sec></sec><sec sec-type="conclusions" id="sec6-vaccines-09-01403"><title>6. Conclusions</title><p>Bovine respiratory disease is a major threat to dairy and beef farming on a global scale and is the leading cause of mortality and morbidity in cattle over 1 month of age [<xref rid="B181-vaccines-09-01403" ref-type="bibr">181</xref>]. Currently, the commercially available vaccines against BRD are limited in their efficacy, as evidenced by the development of clinical disease regardless of vaccination. This is despite advances in understanding pathogenesis, aetiological agents, vaccine technologies and biosecurity measures [<xref rid="B3-vaccines-09-01403" ref-type="bibr">3</xref>]. This limited efficacy may be due to a combination inappropriate administration routes, unsuitable vaccine storage and the challenges of inoculating in young calves. Further, major obstacles in successful vaccine design can come from a combination of host immunity factors, pathogen characteristics and necessary on-farm practices. </p><p>However, on a global scale the population is projected to grow exponentially with an estimated 70&#8211;100% increase in food production required to satisfy this growth [<xref rid="B182-vaccines-09-01403" ref-type="bibr">182</xref>]. To compound the problem of food security from rising demand, employment in agriculture has been on the decline since the 1900s [<xref rid="B183-vaccines-09-01403" ref-type="bibr">183</xref>,<xref rid="B184-vaccines-09-01403" ref-type="bibr">184</xref>]. The demand for additional food from fewer resources is a problem intrinsically linked to socio-economics, climate change, agriculture and resource or land use [<xref rid="B185-vaccines-09-01403" ref-type="bibr">185</xref>].</p><p>The UK relies heavily on agriculture as a source of income for the economy&#8212;in 2020 the total income from farming was estimated to be &#163;4119 million [<xref rid="B186-vaccines-09-01403" ref-type="bibr">186</xref>]. Using Northern Ireland as an example, agriculture accounts for 1.7% of Gross Value Added (GVA), approximately 3 times above the UK average, and has been identified as a key future source of economic development in the &#8216;Going for Growth&#8217; agri-food strategy [<xref rid="B187-vaccines-09-01403" ref-type="bibr">187</xref>]. However, the intensification necessary to realise this drive for economic growth has resulted in increasing farm size against a backdrop of decreasing farm numbers [<xref rid="B188-vaccines-09-01403" ref-type="bibr">188</xref>] and this intensification in productivity may lead to an increasing vulnerability to infectious disease. Thus, alongside increasing pressure on farms to intensify production and more rigid control on antibiotic use, research continues to focus on developing more efficacious, next generation vaccines [<xref rid="B189-vaccines-09-01403" ref-type="bibr">189</xref>].</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization: J.L.L.; writing&#8212;original draft preparation: J.L.L.; writing&#8212;review and editing: J.L.L. and M.J.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research received no external funding</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are collected from the cited literature.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><app-group><app id="app1-vaccines-09-01403"><title>Appendix A</title><table-wrap position="anchor" id="vaccines-09-01403-t0A1" orientation="portrait"><object-id pub-id-type="pii">vaccines-09-01403-t0A1_Table A1</object-id><label>Table A1</label><caption><p>Monovalent vaccines for bovine respiratory disease.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Bovalto Pastobov (2007; Vm 08327/4173)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N&#8212;<italic toggle="yes">Mannheimia haemolytica</italic> (formerly <italic toggle="yes">Pasteurella haemolytica</italic>)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Type A1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Minimum 4 weeks, booster 28 days later</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sub-cutaneous or intramuscular</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipients:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aluminium hydroxide (4.2 mg), thiomersal, salts, water</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Bovela lyophilisate (EU/2/14/176/001-016)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N&#8212;BVDV (1&#8212;non cyto KE-9; 2&#8212;non cyto NY-93)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Modified live (both strains)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 months +</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipients:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not detailed</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Bovilis BVDV suspension (1999; Vm06376/4025)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N&#8212;BVDV 1 (non cyto C-86)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 months</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipients:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Aluminium 3+ (Alum hydroxide) 6&#8211;9 mg</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>BOVILIS IBR marker inac (2006; vm06376/4053)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N&#8212;BHV-1 (GK/D gE negative strain)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 months onwards</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipients:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alum 3+ (6.0&#8211;8.8 mg) formaldehyde 0.6&#8211;1 mg, trometamol</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>BOVILIS IBR MARKER LIVE (2006, vm06376/4032)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N&#8212;BHV-1 (GK/D strain, gE negative)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 wk (Intranasal) 12 wk (Intramuscular)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranasal or Intramuscular</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipients:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sorbitol, monosodium glutamate; glycine</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>HIPRABOVIS IBR marker live (2011; eu/2/10/114/001)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N&#8212;BHV-1 (gE deleted; Ceddel strain)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 wk +</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipients:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not disclosed</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>NASYM (EU/2/19/241/001-004</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N&#8212;BRSV (LYM-56)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9d (Intranasal) 10w (intramuscular)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranasal OR Intramuscular</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipients:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not disclosed</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>RISPOVAL IBR MARKER (VM42058/4127, 1999)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N&#8212;BHV-1 (gE deleted, Difivac Strain)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2w&#8211;3 m (if later than use 3rd booster)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sub cut Sub-cutaneous</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipients:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QUIL A (0.25 MG) ALUM HYDROX (14&#8211;24 MG)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Rispoval Pateurella (VM42058/4128, 1999)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N&#8212;Man.H type A1 (NL 1009 strain)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 wk +</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipients:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liquid paraffin and alum hydrox</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Rispoval RS (vm 42058/4129, 2005)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N&#8212;BRSV (RB94)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live attenuated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7d&#8211;4m (If 7d then 3rd booster to counteract MDA)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipients:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not detailed</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Tracherine (VM42058/4156; 2010)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N&#8212;IBR (RBL106)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live attenuated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3w (10 wk ideally for reduced MDA interference)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranasal</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipients:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not detailed</td></tr></tbody></table></table-wrap><table-wrap position="anchor" id="vaccines-09-01403-t0A2" orientation="portrait"><object-id pub-id-type="pii">vaccines-09-01403-t0A2_Table A2</object-id><label>Table A2</label><caption><p>Poly/Multivalent vaccines for bovine respiratory disease.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Bovalto Respi 3 (2016) (Vm 08327/4273)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y&#8212;BRSV (BiO-24) and BPIV-3 (BiO-23) Man.H (A1)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All inactivated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In cattle devoid of MDA (~6 months)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sub-cutaneous</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipients:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AH (8.0 mg) Quil A (0.4 mg) Thiomersal (0.2 mg) Formaldehyde (1.0 mg)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Bovalto Respi 4 (2016; Vm 08327/4274)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y&#8212;BRSV (BiO24) BBPIV-3V (Bio23) Man H (A1) BVDVV (Bio25)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All inactivated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 wk+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sub-cutaneous</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipients:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AH (8.0 mg) Quil A (0.4 mg) Thiomersal (0.2 mg) Formaldehyde (1.0 mg)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Bovalto Respi Intranasal (2018; Vm 08327/4289)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y&#8212;BPIV-3 (Bio23/A) BRSV (Bio24/A)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Modified live (both)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 day +</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranasal</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipients:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not detailed</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Bovilis bovipast rsp (1999; Vm 01708/4458)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y&#8212;BRSV (ev908) BPIV-3 (sf-4 reisinger) Man.H A1 (cross reactive to A6)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All inactivated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~2 wks of age, prior to housing</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sub-cutaneous</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipients:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alum hydr (37.5 mg) Quil A (0.625 mg) Thiomersal (0.032&#8211;0.58 mg)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>IMURESP-RP (vm 42058/4072 2005)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y&#8212;BPIV-3 (ts RLB103) IBR (ts RLB106)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Live attenuated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3&#8211;10 wk but 10+ wk preferred</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranasal</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipients:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not disclosed</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Rispoval 3 (vm 42058/4124; 2005)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y&#8212;BPIV-3 (RLB103) BRSV (375) BVDVV (type 1 5960 c + 6309 n-c)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Modified live (BPIV-3, BRSV) inactivated BVDV</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 wk+</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipients:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alhydrogel 2% 0.8 mL (equiv. of 24.36 mg alum hydroxide)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Rispoval 4 (VM42058/4125, 2001)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y&#8212;As above (17) including IBR/BHV-1</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactivated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 wk +</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intramuscular</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipients:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not detailed</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Name:</p></list-item></list>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Rispoval RS + BPIV-3 (VM42058/4130)</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multivalent:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Y&#8212;BRSV (375) and BPIV-3 (ts RLB103)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antigen:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Modified Live</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recommended age:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 day +</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route of administration:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intranasal</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/excipient:</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not disclosed</td></tr></tbody></table><table-wrap-foot><fn><p>ts = temperature sensitive; c = cytopathic, n-c = non-cytopathic.</p></fn></table-wrap-foot></table-wrap></app></app-group><ref-list><title>References</title><ref id="B1-vaccines-09-01403"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Callan</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Garry</surname><given-names>F.B.</given-names></name></person-group><article-title>Biosecurity and bovine respiratory disease</article-title><source>Veter. Clin Food Anim. Pract.</source><year>2002</year><volume>18</volume><fpage>57</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/S0749-0720(02)00004-X</pub-id><pub-id pub-id-type="pmcid">PMC7126375</pub-id><pub-id pub-id-type="pmid">12064169</pub-id></element-citation></ref><ref id="B2-vaccines-09-01403"><label>2.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>P.</given-names></name></person-group><article-title>Respiratory Disease in Dairy and Beef Rearer Units</article-title><year>2016</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.nadis.org.uk/4804" ext-link-type="uri">www.nadis.org.uk/4804</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-11-17">(accessed on 17 November 2018)</date-in-citation></element-citation></ref><ref id="B3-vaccines-09-01403"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Pendell</surname><given-names>D.L.</given-names></name></person-group><article-title>Market Impacts of Reducing the Prevalence of Bovine Respiratory Disease in United States Beef Cattle Feedlots</article-title><source>Front. Veter. Sci.</source><year>2017</year><volume>4</volume><fpage>189</fpage><pub-id pub-id-type="doi">10.3389/fvets.2017.00189</pub-id><pub-id pub-id-type="pmid">29170739</pub-id><pub-id pub-id-type="pmcid">PMC5684707</pub-id></element-citation></ref><ref id="B4-vaccines-09-01403"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blakebrough-Hall</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mcmeniman</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>L.A.</given-names></name></person-group><article-title>Economics of Animal Production: An evaluation of the economic effects of bovine respiratory disease on animal performance, carcass traits and economic outcomes in feedlot cattle defined using four BRD diagnosis methods</article-title><source>J. Anim. Sci.</source><year>2020</year><volume>98</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1093/jas/skaa005</pub-id><pub-id pub-id-type="pmcid">PMC6996507</pub-id><pub-id pub-id-type="pmid">31930299</pub-id></element-citation></ref><ref id="B5-vaccines-09-01403"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamdi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>V.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>George</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dhama</surname><given-names>K.</given-names></name></person-group><article-title>Immunofluorescence and molecular diagnosis of bovine respiratory syncytial virus and bovine parainfluenza virus in the naturally infected young cattle and buffaloes from India</article-title><source>Microb. Pathog.</source><year>2020</year><volume>145</volume><fpage>104165</fpage><pub-id pub-id-type="doi">10.1016/j.micpath.2020.104165</pub-id><pub-id pub-id-type="pmid">32205208</pub-id><pub-id pub-id-type="pmcid">PMC7118649</pub-id></element-citation></ref><ref id="B6-vaccines-09-01403"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Timsit</surname><given-names>E.</given-names></name><name name-style="western"><surname>Workentine</surname><given-names>M.</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>T.</given-names></name></person-group><article-title>Distinct bacterial metacommunities inhabit the upper and lower respiratory tracts of healthy feedlot cattle and those diagnosed with bronchopneumonia</article-title><source>Veter. Microbiol.</source><year>2018</year><volume>221</volume><fpage>105</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2018.06.007</pub-id><pub-id pub-id-type="pmid">29981695</pub-id></element-citation></ref><ref id="B7-vaccines-09-01403"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kur&#263;ubi&#263;</surname><given-names>V.</given-names></name><name name-style="western"><surname>&#272;okovi&#263;</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ili&#263;</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Petrovi&#263;</surname><given-names>M.</given-names></name></person-group><article-title>Etiopathogenesis and economic significance of bovine respiratory disease complex (BRDC)</article-title><source>Acta Agric. Serbica</source><year>2018</year><volume>23</volume><fpage>85</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.5937/AASer1845085K</pub-id></element-citation></ref><ref id="B8-vaccines-09-01403"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delabouglise</surname><given-names>A.</given-names></name><name name-style="western"><surname>James</surname><given-names>A.</given-names></name><name name-style="western"><surname>Valarcher</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>H&#228;gglund</surname><given-names>S.</given-names></name><name name-style="western"><surname>Raboisson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rushton</surname><given-names>J.</given-names></name></person-group><article-title>Linking disease epidemiology and livestock productivity: The case of bovine respiratory disease in France</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0189090</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0189090</pub-id><pub-id pub-id-type="pmid">29206855</pub-id><pub-id pub-id-type="pmcid">PMC5716546</pub-id></element-citation></ref><ref id="B9-vaccines-09-01403"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kudirkiene</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aagaard</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Pansri</surname><given-names>P.</given-names></name><name name-style="western"><surname>Krogh</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>J.E.</given-names></name></person-group><article-title>Occurrence of major and minor pathogens in calves diagnosed with bovine respiratory disease</article-title><source>Veter. Microbiol.</source><year>2021</year><volume>259</volume><fpage>109135</fpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2021.109135</pub-id><pub-id pub-id-type="pmid">34090248</pub-id></element-citation></ref><ref id="B10-vaccines-09-01403"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steiner</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meylan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lava</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sch&#252;pbach</surname><given-names>G.</given-names></name></person-group><article-title>Antimicrobial drug use and risk factors associated with treatment incidence and mortality in Swiss veal calves reared under improved welfare conditions</article-title><source>Prev. Vet. Med.</source><year>2016</year><volume>126</volume><fpage>121</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.7892/boris.80404</pub-id><pub-id pub-id-type="pmid">26897245</pub-id></element-citation></ref><ref id="B11-vaccines-09-01403"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makoschey</surname><given-names>B.</given-names></name><name name-style="western"><surname>Berge</surname><given-names>A.C.</given-names></name></person-group><article-title>Review on bovine respiratory syncytial virus and bovine parainfluenza &#8211; usual suspects in bovine respiratory disease&#8212;A narrative review</article-title><source>BMC Veter. Res.</source><year>2021</year><volume>17</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1186/s12917-021-02935-5</pub-id><pub-id pub-id-type="pmid">34332574</pub-id><pub-id pub-id-type="pmcid">PMC8325295</pub-id></element-citation></ref><ref id="B12-vaccines-09-01403"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bell</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Blackburn</surname><given-names>P.</given-names></name><name name-style="western"><surname>Elliott</surname><given-names>M.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>T.I.A.P.</given-names></name><name name-style="western"><surname>Ellison</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lahuerta-Marin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ball</surname><given-names>H.J.</given-names></name></person-group><article-title>Investigation of polymerase chain reaction assays to improve detection of bacterial involvement in bovine respiratory disease</article-title><source>J. Veter. Diagn. Investig.</source><year>2014</year><volume>26</volume><fpage>631</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1177/1040638714540166</pub-id><pub-id pub-id-type="pmid">25012080</pub-id></element-citation></ref><ref id="B13-vaccines-09-01403"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baptista</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Rezende</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>P.D.A.</given-names></name><name name-style="western"><surname>Massi</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Nogueira</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Magalh&#227;es</surname><given-names>L.Q.</given-names></name><name name-style="western"><surname>Headley</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Menezes</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Alfieri</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Saut</surname><given-names>J.P.E.</given-names></name></person-group><article-title>Bovine respiratory disease complex associated mortality and morbidity rates in feedlot cattle from southeastern Brazil</article-title><source>J. Infect. Dev. Ctries.</source><year>2017</year><volume>11</volume><fpage>791</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.3855/jidc.9296</pub-id><pub-id pub-id-type="pmid">31600152</pub-id></element-citation></ref><ref id="B14-vaccines-09-01403"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glover</surname><given-names>I.D.</given-names></name></person-group><article-title>Improving calf-side diagnosis of respiratory disease on UK dairy farms</article-title><source>Livestock</source><year>2017</year><volume>22</volume><fpage>230</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.12968/live.2017.22.5.230</pub-id></element-citation></ref><ref id="B15-vaccines-09-01403"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavirani</surname><given-names>S.</given-names></name></person-group><article-title>Immunization of calves and herd immunity to Bovine respiratory Disease Complex (BRDC)</article-title><source>Large Anim. Rev.</source><year>2019</year><volume>25</volume><fpage>17</fpage><lpage>24</lpage></element-citation></ref><ref id="B16-vaccines-09-01403"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saade</surname><given-names>G.</given-names></name><name name-style="western"><surname>Deblanc</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bougon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marois-Cr&#233;han</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fablet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Auray</surname><given-names>G.</given-names></name><name name-style="western"><surname>Belloc</surname><given-names>C.</given-names></name><name name-style="western"><surname>Leblanc-Maridor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gagnon</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Coinfections and their molecular consequences in the porcine respiratory tract</article-title><source>Veter. Res.</source><year>2020</year><volume>51</volume><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1186/s13567-020-00807-8</pub-id><pub-id pub-id-type="pmcid">PMC7296899</pub-id><pub-id pub-id-type="pmid">32546263</pub-id></element-citation></ref><ref id="B17-vaccines-09-01403"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tibbo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Woldemeskel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gopilo</surname><given-names>A.</given-names></name></person-group><article-title>An outbreak of respiratory disease complex in sheep in Central Ethiopia</article-title><source>Trop. Anim. Health Prod.</source><year>2001</year><volume>33</volume><fpage>355</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1023/A:1010565905004</pub-id><pub-id pub-id-type="pmid">11556615</pub-id></element-citation></ref><ref id="B18-vaccines-09-01403"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>P.R.</given-names></name></person-group><article-title>Treatment and Control of Respiratory Disease in Sheep</article-title><source>Veter. Food Anim. Pract.</source><year>2011</year><volume>27</volume><fpage>175</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.cvfa.2010.10.016</pub-id><pub-id pub-id-type="pmid">21215901</pub-id></element-citation></ref><ref id="B19-vaccines-09-01403"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reagan</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Sykes</surname><given-names>J.E.</given-names></name></person-group><article-title>Canine Infectious Respiratory Disease</article-title><source>Veter. Food Anim. Pract.</source><year>2020</year><volume>50</volume><fpage>405</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1016/j.cvsm.2019.10.009</pub-id><pub-id pub-id-type="pmid">31813556</pub-id><pub-id pub-id-type="pmcid">PMC7132485</pub-id></element-citation></ref><ref id="B20-vaccines-09-01403"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohn</surname><given-names>L.A.</given-names></name></person-group><article-title>Feline Respiratory Disease Complex</article-title><source>Veter. Clin. N. Am. Anim. Pract.</source><year>2011</year><volume>41</volume><fpage>1273</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1016/j.cvsm.2011.07.006</pub-id><pub-id pub-id-type="pmid">22041216</pub-id></element-citation></ref><ref id="B21-vaccines-09-01403"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bryson</surname><given-names>D.</given-names></name></person-group><article-title>Calf Pneumonia</article-title><source>Veter. Clin. N. Am. Food Anim. Pract.</source><year>1985</year><volume>1</volume><fpage>237</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1016/S0749-0720(15)31326-8</pub-id><pub-id pub-id-type="pmcid">PMC7135460</pub-id><pub-id pub-id-type="pmid">3907774</pub-id></element-citation></ref><ref id="B22-vaccines-09-01403"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsen</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Tegtmeier</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>E.</given-names></name></person-group><article-title>Bovine respiratory syncytial virus (BRSV) pneumonia in beef herds despite vaccination</article-title><source>Acta Veter. Scand.</source><year>2001</year><volume>42</volume><fpage>113</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1186/1751-0147-42-113</pub-id><pub-id pub-id-type="pmid">11455891</pub-id><pub-id pub-id-type="pmcid">PMC2202333</pub-id></element-citation></ref><ref id="B23-vaccines-09-01403"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gershwin</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Berghaus</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>K.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Corbeil</surname><given-names>L.B.</given-names></name></person-group><article-title>Immune mechanisms of pathogenetic synergy in concurrent bovine pulmonary infection with Haemophilus somnus and bovine respiratory syncytial virus</article-title><source>Veter. Immunol. Immunopathol.</source><year>2005</year><volume>107</volume><fpage>119</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.vetimm.2005.04.004</pub-id><pub-id pub-id-type="pmid">15979157</pub-id></element-citation></ref><ref id="B24-vaccines-09-01403"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beadling</surname><given-names>C.</given-names></name><name name-style="western"><surname>Slifka</surname><given-names>M.K.</given-names></name></person-group><article-title>How do viral infections predispose patients to bacterial infections?</article-title><source>Curr. Opin. Infect. Dis.</source><year>2004</year><volume>17</volume><fpage>185</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1097/00001432-200406000-00003</pub-id><pub-id pub-id-type="pmid">15166819</pub-id></element-citation></ref><ref id="B25-vaccines-09-01403"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manohar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Loh</surname><given-names>B.</given-names></name><name name-style="western"><surname>Athira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nachimuthu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>X.</given-names></name><name name-style="western"><surname>Welburn</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Leptihn</surname><given-names>S.</given-names></name></person-group><article-title>Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics?</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><fpage>1434</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2020.01434</pub-id><pub-id pub-id-type="pmid">32733404</pub-id><pub-id pub-id-type="pmcid">PMC7358648</pub-id></element-citation></ref><ref id="B26-vaccines-09-01403"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bell</surname><given-names>R.</given-names></name><name name-style="western"><surname>Turkington</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cosby</surname><given-names>S.</given-names></name></person-group><article-title>The Bacterial and Viral Agents of BRDC: Immune Evasion and Vaccine Developments</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>337</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9040337</pub-id><pub-id pub-id-type="pmid">33916119</pub-id><pub-id pub-id-type="pmcid">PMC8066859</pub-id></element-citation></ref><ref id="B27-vaccines-09-01403"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hulbert</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Mois&#225;</surname><given-names>S.J.</given-names></name></person-group><article-title>Stress, immunity, and the management of calves</article-title><source>J. Dairy Sci.</source><year>2016</year><volume>99</volume><fpage>3199</fpage><lpage>3216</lpage><pub-id pub-id-type="doi">10.3168/jds.2015-10198</pub-id><pub-id pub-id-type="pmid">26805993</pub-id></element-citation></ref><ref id="B28-vaccines-09-01403"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van der Fels-Klerx</surname><given-names>H.</given-names></name><name name-style="western"><surname>Horst</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dijkhuizen</surname><given-names>A.</given-names></name></person-group><article-title>Risk factors for bovine respiratory disease in dairy youngstock in The Netherlands: The perception of experts</article-title><source>Livest. Prod. Sci.</source><year>2000</year><volume>66</volume><fpage>35</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/S0301-6226(00)00163-9</pub-id></element-citation></ref><ref id="B29-vaccines-09-01403"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinchak</surname><given-names>W.E.</given-names></name><name name-style="western"><surname>Tolleson</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>McCloy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Ansley</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Bevers</surname><given-names>S.J.</given-names></name></person-group><article-title>Morbidity effects on productivity and profitability of stocker cattle grazing in the Southern Plains</article-title><source>J. Anim. Sci.</source><year>2004</year><volume>82</volume><fpage>2773</fpage><lpage>2779</lpage><pub-id pub-id-type="doi">10.2527/2004.8292773x</pub-id><pub-id pub-id-type="pmid">15446494</pub-id></element-citation></ref><ref id="B30-vaccines-09-01403"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Fulton</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Lehenbauer</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Step</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Confer</surname><given-names>A.W.</given-names></name></person-group><article-title>The epidemiology of bovine respiratory disease: What is the evidence for preventive measures?</article-title><source>Can. Veter. J.</source><year>2010</year><volume>51</volume><fpage>1351</fpage><lpage>1359</lpage><pub-id pub-id-type="pmcid">PMC2978987</pub-id><pub-id pub-id-type="pmid">21358927</pub-id></element-citation></ref><ref id="B31-vaccines-09-01403"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribble</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Meek</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Janzen</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Guichon</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Jim</surname><given-names>G.K.</given-names></name></person-group><article-title>Effect of time of year, weather, and the pattern of auction market sales on fatal fibrinous pneumonia (shipping fever) in calves in a large feedlot in Alberta (1985&#8211;1988)</article-title><source>Can. J. Veter. Res.</source><year>1995</year><volume>59</volume><fpage>167</fpage><lpage>172</lpage><pub-id pub-id-type="pmcid">PMC1263760</pub-id><pub-id pub-id-type="pmid">8521347</pub-id></element-citation></ref><ref id="B32-vaccines-09-01403"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacVean</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Franzen</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Keefe</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>B.W.</given-names></name></person-group><article-title>Airborne particle concentration and meteorologic conditions associated with pneumonia incidence in feedlot cattle</article-title><source>Am. J. Veter. Res.</source><year>1986</year><volume>47</volume><fpage>2676</fpage><lpage>2682</lpage><pub-id pub-id-type="pmid">3800131</pub-id></element-citation></ref><ref id="B33-vaccines-09-01403"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexander</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>MacVean</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Salman</surname><given-names>M.D.</given-names></name></person-group><article-title>Risk factors for lower respiratory tract disease in a cohort of feedlot cattle</article-title><source>J. Am. Veter. Med Assoc.</source><year>1989</year><volume>195</volume><fpage>207</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">2768036</pub-id></element-citation></ref><ref id="B34-vaccines-09-01403"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#228;rtel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nikunen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tanskanen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kivel&#228;</surname><given-names>S.-L.</given-names></name><name name-style="western"><surname>Aho</surname><given-names>P.</given-names></name><name name-style="western"><surname>Soveri</surname><given-names>T.</given-names></name><name name-style="western"><surname>Saloniemi</surname><given-names>H.</given-names></name></person-group><article-title>Viral and Bacterial Pathogens in Bovine Respiratory Disease in Finland</article-title><source>Acta Veter. Scand.</source><year>2004</year><volume>45</volume><fpage>193</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1186/1751-0147-45-193</pub-id><pub-id pub-id-type="pmcid">PMC1820993</pub-id><pub-id pub-id-type="pmid">15663079</pub-id></element-citation></ref><ref id="B35-vaccines-09-01403"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hay</surname><given-names>K.</given-names></name><name name-style="western"><surname>Morton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schibrowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clements</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mahony</surname><given-names>T.</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>T.</given-names></name></person-group><article-title>Associations between prior management of cattle and risk of bovine respiratory disease in feedlot cattle</article-title><source>Prev. Veter. Med.</source><year>2016</year><volume>127</volume><fpage>37</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.prevetmed.2016.02.006</pub-id><pub-id pub-id-type="pmid">27094138</pub-id></element-citation></ref><ref id="B36-vaccines-09-01403"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#228;gglund</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hjort</surname><given-names>M.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>D.</given-names></name><name name-style="western"><surname>&#214;hagen</surname><given-names>P.</given-names></name><name name-style="western"><surname>T&#246;rnquist</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alenius</surname><given-names>S.</given-names></name></person-group><article-title>A six-year study on respiratory viral infections in a bull testing facility</article-title><source>Veter. J.</source><year>2007</year><volume>173</volume><fpage>585</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1016/j.tvjl.2006.02.010</pub-id><pub-id pub-id-type="pmid">16647871</pub-id><pub-id pub-id-type="pmcid">PMC7110487</pub-id></element-citation></ref><ref id="B37-vaccines-09-01403"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hotchkiss</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Dagleish</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Willoughby</surname><given-names>K.</given-names></name><name name-style="western"><surname>McKendrick</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Finlayson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zadoks</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Newsome</surname><given-names>E.</given-names></name><name name-style="western"><surname>Brulisauer</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gunn</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Hodgson</surname><given-names>J.C.</given-names></name></person-group><article-title>Prevalence of Pasteurella multocidaand other respiratory pathogens in the nasal tract of Scottish calves</article-title><source>Veter. Rec.</source><year>2010</year><volume>167</volume><fpage>555</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1136/vr.c4827</pub-id><pub-id pub-id-type="pmid">21257416</pub-id></element-citation></ref><ref id="B38-vaccines-09-01403"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neibergs</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Seabury</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Wojtowicz</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Scraggs</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kiser</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Neupane</surname><given-names>M.</given-names></name><name name-style="western"><surname>E Womack</surname><given-names>J.</given-names></name><name name-style="western"><surname>Van Eenennaam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hagevoort</surname><given-names>G.R.</given-names></name><etal/></person-group><article-title>Susceptibility loci revealed for bovine respiratory disease complex in pre-weaned holstein calves</article-title><source>BMC Genom.</source><year>2014</year><volume>15</volume><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1186/1471-2164-15-1164</pub-id><pub-id pub-id-type="pmid">25534905</pub-id><pub-id pub-id-type="pmcid">PMC4445561</pub-id></element-citation></ref><ref id="B39-vaccines-09-01403"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>D.</given-names></name><name name-style="western"><surname>Earley</surname><given-names>B.</given-names></name><name name-style="western"><surname>McCabe</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lemon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>C.</given-names></name><name name-style="western"><surname>McMenamy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cosby</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Blackshields</surname><given-names>G.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Experimental challenge with bovine respiratory syncytial virus in dairy calves: Bronchial lymph node transcriptome response</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/s41598-019-51094-z</pub-id><pub-id pub-id-type="pmid">31611566</pub-id><pub-id pub-id-type="pmcid">PMC6791843</pub-id></element-citation></ref><ref id="B40-vaccines-09-01403"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>D.</given-names></name><name name-style="western"><surname>Earley</surname><given-names>B.</given-names></name><name name-style="western"><surname>McCabe</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Lemon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>C.</given-names></name><name name-style="western"><surname>McMenamy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cosby</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>S.M.</given-names></name></person-group><article-title>Messenger RNA biomarkers of Bovine Respiratory Syncytial Virus infection in the whole blood of dairy calves</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/s41598-021-88878-1</pub-id><pub-id pub-id-type="pmid">33931718</pub-id><pub-id pub-id-type="pmcid">PMC8087838</pub-id></element-citation></ref><ref id="B41-vaccines-09-01403"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitra</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cernicchiaro</surname><given-names>N.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hause</surname><given-names>B.</given-names></name></person-group><article-title>Metagenomic characterisation of the virome associated with bovine respiratory disease in feedlot cattle identified novel viruses and suggests an etiologic role for influenza D virus</article-title><source>J. Gen. Virol.</source><year>2016</year><volume>97</volume><fpage>1771</fpage><lpage>1784</lpage><pub-id pub-id-type="doi">10.1099/jgv.0.000492</pub-id><pub-id pub-id-type="pmid">27154756</pub-id><pub-id pub-id-type="pmcid">PMC5772826</pub-id></element-citation></ref><ref id="B42-vaccines-09-01403"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dane</surname><given-names>H.</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guelbenzu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hause</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Forster</surname><given-names>F.</given-names></name><name name-style="western"><surname>McMenamy</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lemon</surname><given-names>K.</given-names></name></person-group><article-title>Detection of influenza D virus in bovine respiratory disease samples, UK</article-title><source>Transbound. Emerg. Dis.</source><year>2019</year><volume>66</volume><fpage>2184</fpage><lpage>2187</lpage><pub-id pub-id-type="doi">10.1111/tbed.13273</pub-id><pub-id pub-id-type="pmid">31228318</pub-id><pub-id pub-id-type="pmcid">PMC7168542</pub-id></element-citation></ref><ref id="B43-vaccines-09-01403"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellis</surname><given-names>J.A.</given-names></name></person-group><article-title>Update on viral pathogenesis in BRD</article-title><source>Anim. Health. Res. Rev.</source><year>2009</year><volume>10</volume><fpage>149</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1017/S146625230999020X</pub-id><pub-id pub-id-type="pmid">20003652</pub-id></element-citation></ref><ref id="B44-vaccines-09-01403"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prysliak</surname><given-names>T.</given-names></name><name name-style="western"><surname>van der Merwe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lawman</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Townsend</surname><given-names>H.</given-names></name></person-group><article-title>Respiratory disease caused by Mycoplasma bovis is enhanced by exposure to bovine herpes virus 1 (BHV-1) but not to bovine viral diarrhea virus (BVDV) type 2</article-title><source>Can. Veter. J.</source><year>2011</year><volume>52</volume><fpage>1195</fpage><comment>ISSN: 0008-5286</comment><pub-id pub-id-type="pmcid">PMC3196011</pub-id><pub-id pub-id-type="pmid">22547839</pub-id></element-citation></ref><ref id="B45-vaccines-09-01403"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fahkrajang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sudaryatma</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Mekata</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hamabe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>A.</given-names></name><name name-style="western"><surname>Okabayashi</surname><given-names>T.</given-names></name></person-group><article-title>Bovine respiratory coronavirus enhances bacterial adherence by upregulating expression of cellular receptors on bovine respiratory epithelial cells</article-title><source>Veter. Microbiol.</source><year>2021</year><volume>255</volume><fpage>109017</fpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2021.109017</pub-id><pub-id pub-id-type="pmid">33639390</pub-id><pub-id pub-id-type="pmcid">PMC9759695</pub-id></element-citation></ref><ref id="B46-vaccines-09-01403"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohlson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Alenius</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tr&#229;v&#233;n</surname><given-names>M.</given-names></name><name name-style="western"><surname>Emanuelson</surname><given-names>U.</given-names></name></person-group><article-title>A longitudinal study of the dynamics of bovine corona virus and respiratory syncytial virus infections in dairy herds</article-title><source>Veter. J.</source><year>2013</year><volume>197</volume><fpage>395</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1016/j.tvjl.2013.01.028</pub-id><pub-id pub-id-type="pmid">23481616</pub-id><pub-id pub-id-type="pmcid">PMC7110841</pub-id></element-citation></ref><ref id="B47-vaccines-09-01403"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uttenthal</surname><given-names>&#197;.</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Philipsen</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Tj&#248;rneh&#248;j</surname><given-names>K.</given-names></name><name name-style="western"><surname>Viuff</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>T.K.</given-names></name></person-group><article-title>Antibody dynamics in BRSV-infected Danish dairy herds as determined by isotype-specific immunoglobulins</article-title><source>Veter. Microbiol.</source><year>2000</year><volume>76</volume><fpage>329</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/S0378-1135(00)00261-3</pub-id><pub-id pub-id-type="pmcid">PMC7117174</pub-id><pub-id pub-id-type="pmid">11000530</pub-id></element-citation></ref><ref id="B48-vaccines-09-01403"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Teegarden</surname><given-names>R.</given-names></name><name name-style="western"><surname>MacVean</surname><given-names>D.</given-names></name><name name-style="western"><surname>Salman Smith</surname><given-names>G.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>G.</given-names></name></person-group><article-title>Prevalence and specificity of antibodies to bovine respiratory syncytial virus in sera from feedlot and range cattle</article-title><source>Am. J. Veter. Res.</source><year>1988</year><volume>49</volume><fpage>1316</fpage><lpage>1319</lpage><pub-id pub-id-type="pmid">3178027</pub-id></element-citation></ref><ref id="B49-vaccines-09-01403"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Obando</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hidalgo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Merza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Montoya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Klingeborn</surname><given-names>B.</given-names></name><name name-style="western"><surname>Moreno-L&#243;pez</surname><given-names>J.</given-names></name></person-group><article-title>Seroprevalence to bovine virus diarrhoea virus and other viruses of the bovine respiratory complex in Venezuela (Apure State)</article-title><source>Prev. Veter. Med.</source><year>1999</year><volume>41</volume><fpage>271</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1016/S0167-5877(99)00049-5</pub-id><pub-id pub-id-type="pmid">10530426</pub-id></element-citation></ref><ref id="B50-vaccines-09-01403"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sol&#237;s-Calder&#243;n</surname><given-names>J.</given-names></name><name name-style="western"><surname>Segura-Correa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Aguilar-Romero</surname><given-names>F.</given-names></name><name name-style="western"><surname>Segura-Correa</surname><given-names>V.</given-names></name></person-group><article-title>Detection of antibodies and risk factors for infection with bovine respiratory syncytial virus and parainfluenza virus-3 in beef cattle of Yucatan, Mexico</article-title><source>Prev. Veter. Med.</source><year>2007</year><volume>82</volume><fpage>102</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1016/j.prevetmed.2007.05.013</pub-id><pub-id pub-id-type="pmid">17590461</pub-id></element-citation></ref><ref id="B51-vaccines-09-01403"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimman</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Westenbrink</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schreuder</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Straver</surname><given-names>P.J.</given-names></name></person-group><article-title>Local and systemic antibody response to bovine respiratory syncytial virus infection and reinfection in calves with and without maternal antibodies</article-title><source>J. Clin. Microbiol.</source><year>1987</year><volume>25</volume><fpage>1097</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1128/jcm.25.6.1097-1106.1987</pub-id><pub-id pub-id-type="pmid">2954996</pub-id><pub-id pub-id-type="pmcid">PMC269144</pub-id></element-citation></ref><ref id="B52-vaccines-09-01403"><label>52.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Office of Animal Health</collab></person-group><source>Compendium of Data Sheets for Animal Medicines 2021</source><publisher-name>National Office of Animal Health</publisher-name><publisher-loc>Enfield, UK</publisher-loc><year>2021</year><size units="pages">1584p</size></element-citation></ref><ref id="B53-vaccines-09-01403"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chase</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Hurley</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Reber</surname><given-names>A.J.</given-names></name></person-group><article-title>Neonatal Immune Development in the Calf and Its Impact on Vaccine Response</article-title><source>Veter. Clin. N. Am. Food Anim. Pract.</source><year>2008</year><volume>24</volume><fpage>87</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.cvfa.2007.11.001</pub-id><pub-id pub-id-type="pmcid">PMC7127081</pub-id><pub-id pub-id-type="pmid">18299033</pub-id></element-citation></ref><ref id="B54-vaccines-09-01403"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niewiesk</surname><given-names>S.</given-names></name></person-group><article-title>Maternal Antibodies: Clinical Significance, Mechanism of Interference with Immune Responses, and Possible Vaccination Strategies</article-title><source>Front. Immunol.</source><year>2014</year><volume>5</volume><fpage>446</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00446</pub-id><pub-id pub-id-type="pmid">25278941</pub-id><pub-id pub-id-type="pmcid">PMC4165321</pub-id></element-citation></ref><ref id="B55-vaccines-09-01403"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richeson</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Falkner</surname><given-names>T.R.</given-names></name></person-group><article-title>Bovine Respiratory Disease Vaccination: What Is the Effect of Timing?</article-title><source>Veter. Clin. N. Am. Food Anim. Pract.</source><year>2020</year><volume>36</volume><fpage>473</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1016/j.cvfa.2020.03.013</pub-id><pub-id pub-id-type="pmid">32451036</pub-id></element-citation></ref><ref id="B56-vaccines-09-01403"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cortese</surname><given-names>V.S.</given-names></name></person-group><article-title>Neonatal Immunology</article-title><source>Veter. Clin. N. Am. Food Anim. Pract.</source><year>2009</year><volume>25</volume><fpage>221</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/j.cvfa.2008.10.003</pub-id><pub-id pub-id-type="pmid">19174291</pub-id><pub-id pub-id-type="pmcid">PMC7126137</pub-id></element-citation></ref><ref id="B57-vaccines-09-01403"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tregoning</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>J.U.</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Harker</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Goritzka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Openshaw</surname><given-names>P.J.</given-names></name></person-group><article-title>Neonatal antibody responses are attenuated by interferon-&#947; produced by NK and T cells during RSV infection</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>5576</fpage><lpage>5581</lpage><pub-id pub-id-type="doi">10.1073/pnas.1214247110</pub-id><pub-id pub-id-type="pmid">23509276</pub-id><pub-id pub-id-type="pmcid">PMC3619373</pub-id></element-citation></ref><ref id="B58-vaccines-09-01403"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gow</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burdett</surname><given-names>W.</given-names></name><name name-style="western"><surname>Nordstrom</surname><given-names>S.</given-names></name></person-group><article-title>Inhibition of priming for bovine respiratory syncytial virus-specific protective immune responses following parenteral vaccination of passively immune calves</article-title><source>Can. Veter. J.</source><year>2014</year><volume>55</volume><fpage>1180</fpage><lpage>1185</lpage><pub-id pub-id-type="pmcid">PMC4231808</pub-id><pub-id pub-id-type="pmid">25477547</pub-id></element-citation></ref><ref id="B59-vaccines-09-01403"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gershwin</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Behrens</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>McEligot</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Carvallo-Chaigneau</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Crum</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Gunnarson</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Corbeil</surname><given-names>L.B.</given-names></name></person-group><article-title>A recombinant subunit vaccine for bovine RSV and Histophilus somni protects calves against dual pathogen challenge</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>1954</fpage><lpage>1963</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.01.059</pub-id><pub-id pub-id-type="pmid">28274639</pub-id></element-citation></ref><ref id="B60-vaccines-09-01403"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van der Sluijs</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>E.</given-names></name><name name-style="western"><surname>Makoschey</surname><given-names>B.</given-names></name></person-group><article-title>A single vaccination with an inactivated bovine respiratory syncytial virus vaccine primes the cellular immune response in calves with maternal antibody</article-title><source>BMC Veter. Res.</source><year>2010</year><volume>6</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.1186/1746-6148-6-2</pub-id><pub-id pub-id-type="pmcid">PMC2824702</pub-id><pub-id pub-id-type="pmid">20064236</pub-id></element-citation></ref><ref id="B61-vaccines-09-01403"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blod&#246;rn</surname><given-names>K.</given-names></name><name name-style="western"><surname>H&#228;gglund</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fix</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dubuquoy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Makabi-Panzu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Thom</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karlsson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Roque</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Karlstam</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pringle</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Vaccine Safety and Efficacy Evaluation of a Recombinant Bovine Respiratory Syncytial Virus (BRSV) with Deletion of the SH Gene and Subunit Vaccines Based On Recombinant Human RSV Proteins: N-nanorings, P and M2-1, in Calves with Maternal Antibodies</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e100392</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0100392</pub-id><pub-id pub-id-type="pmid">24945377</pub-id><pub-id pub-id-type="pmcid">PMC4063758</pub-id></element-citation></ref><ref id="B62-vaccines-09-01403"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fulton</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>E Briggs</surname><given-names>R.</given-names></name><name name-style="western"><surname>E Payton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Confer</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Saliki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ridpath</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Burge</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Duff</surname><given-names>G.C.</given-names></name></person-group><article-title>Maternally derived humoral immunity to bovine viral diarrhea virus (BVDV) 1a, BVDV1b, BVDV2, bovine herpesvirus-1, parainfluenza-3 virus bovine respiratory syncytial virus, <italic toggle="yes">Mannheimia haemolytica</italic> and <italic toggle="yes">Pasteurella multocida</italic> in beef calves, antibody decline by half-life studies and effect on response to vaccination</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>643</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2003.08.033</pub-id><pub-id pub-id-type="pmid">14741155</pub-id></element-citation></ref><ref id="B63-vaccines-09-01403"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richeson</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Broadway</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>J.A.</given-names></name></person-group><article-title>Vaccination management of beef cattle: Delayed vaccination and Endotoxin stacking</article-title><source>Veter. Clin. Food Anim.</source><year>2019</year><volume>35</volume><fpage>575</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1016/j.cvfa.2019.07.003</pub-id><pub-id pub-id-type="pmcid">PMC7125876</pub-id><pub-id pub-id-type="pmid">31590903</pub-id></element-citation></ref><ref id="B64-vaccines-09-01403"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poulet</surname><given-names>H.</given-names></name><name name-style="western"><surname>Minke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pardo</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Juillard</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nordgren</surname><given-names>B.</given-names></name><name name-style="western"><surname>Audonnet</surname><given-names>J.-C.</given-names></name></person-group><article-title>Development and registration of recombinant veterinary vaccines: The example of the canarypox vector platform</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>5606</fpage><lpage>5612</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.11.066</pub-id><pub-id pub-id-type="pmid">17227690</pub-id></element-citation></ref><ref id="B65-vaccines-09-01403"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gow</surname><given-names>S.</given-names></name><name name-style="western"><surname>West</surname><given-names>K.</given-names></name><name name-style="western"><surname>Waldner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mutwiri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rosenberg</surname><given-names>H.</given-names></name></person-group><article-title>Response of calves to challenge exposure with virulent bovine respiratory syncytial virus following intranasal administration of vaccines formulated for parenteral administration</article-title><source>J. Am. Veter. Med Assoc.</source><year>2007</year><volume>230</volume><fpage>233</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.2460/javma.230.2.233</pub-id><pub-id pub-id-type="pmid">17223757</pub-id></element-citation></ref><ref id="B66-vaccines-09-01403"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Mattei</surname><given-names>R.I.</given-names></name><name name-style="western"><surname>Schllemer</surname><given-names>N.R.</given-names></name><name name-style="western"><surname>Thomaz</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Antunes</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Virmond</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Taube</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Bertagnon</surname><given-names>H.G.</given-names></name></person-group><article-title>The effect of bovine vaccines against respiratory viruses administered either intranasal or intramuscular on broncho-alveolar fluid cells of heifers</article-title><source>Veter. Q.</source><year>2021</year><volume>41</volume><fpage>97</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1080/01652176.2020.1870019</pub-id><pub-id pub-id-type="pmid">33375918</pub-id><pub-id pub-id-type="pmcid">PMC7833023</pub-id></element-citation></ref><ref id="B67-vaccines-09-01403"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Karron</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Belshe</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Crowe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boyce</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Halburnt</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>E.L.</given-names></name><etal/></person-group><article-title>Evaluation of a Live, Cold-Passaged, Temperature-Sensitive, Respiratory Syncytial Virus Vaccine Candidate in Infancy</article-title><source>J. Infect. Dis.</source><year>2000</year><volume>182</volume><fpage>1331</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1086/315859</pub-id><pub-id pub-id-type="pmid">11010838</pub-id></element-citation></ref><ref id="B68-vaccines-09-01403"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henderson</surname><given-names>D.A.</given-names></name></person-group><article-title>The eradication of smallpox&#8212;An overview of the past, present, and future</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><issue>(Suppl. 4)</issue><fpage>D7</fpage><lpage>D9</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.06.080</pub-id><pub-id pub-id-type="pmid">22188929</pub-id></element-citation></ref><ref id="B69-vaccines-09-01403"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kock</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pfeiffer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mariner</surname><given-names>J.</given-names></name><name name-style="western"><surname>McKeever</surname><given-names>D.</given-names></name><name name-style="western"><surname>Oura</surname><given-names>C.</given-names></name><name name-style="western"><surname>Roeder</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Rinderpest eradicated; what next?</article-title><source>Veter. Rec.</source><year>2011</year><volume>169</volume><fpage>10</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1136/vr.d4011</pub-id><pub-id pub-id-type="pmid">21724764</pub-id></element-citation></ref><ref id="B70-vaccines-09-01403"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roeder</surname><given-names>P.L.</given-names></name></person-group><article-title>Rinderpest: The end of cattle plague</article-title><source>Prev. Veter. Med.</source><year>2011</year><volume>102</volume><fpage>98</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.prevetmed.2011.04.004</pub-id><pub-id pub-id-type="pmid">21783268</pub-id></element-citation></ref><ref id="B71-vaccines-09-01403"><label>71.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Sanders</surname><given-names>B.</given-names></name><name name-style="western"><surname>Koldijk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schuitemaker</surname><given-names>H.</given-names></name></person-group><article-title>Inactivated Viral Vaccines</article-title><source>Infectious Disease and Vaccines Therapeutic Area</source><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2015</year><fpage>45</fpage><lpage>80</lpage></element-citation></ref><ref id="B72-vaccines-09-01403"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clem</surname><given-names>A.S.</given-names></name></person-group><article-title>Fundamentals of vaccine immunology</article-title><source>J. Glob. Infect. Dis.</source><year>2011</year><volume>3</volume><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.4103/0974-777X.77299</pub-id><pub-id pub-id-type="pmid">21572612</pub-id><pub-id pub-id-type="pmcid">PMC3068582</pub-id></element-citation></ref><ref id="B73-vaccines-09-01403"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ficht</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Kahl-McDonagh</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Arenas-Gamboa</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Rice-Ficht</surname><given-names>A.C.</given-names></name></person-group><article-title>Brucellosis: The case for live, attenuated vaccines</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>D40</fpage><lpage>D43</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.08.058</pub-id><pub-id pub-id-type="pmid">19837284</pub-id><pub-id pub-id-type="pmcid">PMC2780424</pub-id></element-citation></ref><ref id="B74-vaccines-09-01403"><label>74.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Goldsby</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Kindt</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Osborne</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Kuby</surname><given-names>J.</given-names></name></person-group><source>Immunology, 5th ed</source><publisher-name>Freeman</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2003</year></element-citation></ref><ref id="B75-vaccines-09-01403"><label>75.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>National Institute of Allergy and Infectious Disease</collab></person-group><article-title>Vaccine Types</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.niaid.nih.gov/research/vaccine-types" ext-link-type="uri">https://www.niaid.nih.gov/research/vaccine-types</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-10-10">(accessed on 10 October 2021)</date-in-citation></element-citation></ref><ref id="B76-vaccines-09-01403"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevens</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Burdett</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Bolton</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Nordstrom</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Chase</surname><given-names>C.C.L.</given-names></name></person-group><article-title>Efficacy of a Non-adjuvanted, Modified-live Virus Vaccine in Calves with Maternal Antibodies against a Virulent Bovine Viral Diarrhea Virus Type 2a Challenge Seven Months following Vaccination</article-title><source>Am. Assoc. Bov. Pract.</source><year>2011</year><volume>45</volume><fpage>23</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.21423/bovine-vol45no1p23-31</pub-id></element-citation></ref><ref id="B77-vaccines-09-01403"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salerno-Gon&#231;alves</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sztein</surname><given-names>M.B.</given-names></name></person-group><article-title>Cell-mediated immunity and the challenges for vaccine development</article-title><source>Trends Microbiol.</source><year>2006</year><volume>14</volume><fpage>536</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2006.10.004</pub-id><pub-id pub-id-type="pmid">17055276</pub-id></element-citation></ref><ref id="B78-vaccines-09-01403"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>K.</given-names></name><name name-style="western"><surname>Petrie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Haines</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Konoby</surname><given-names>C.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>K.</given-names></name><name name-style="western"><surname>A Ellis</surname><given-names>J.</given-names></name></person-group><article-title>The effect of formalin-inactivated vaccine on respiratory disease associated with bovine respiratory syncytial virus infection in calves</article-title><source>Vaccine</source><year>1999</year><volume>17</volume><fpage>809</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(98)00265-5</pub-id><pub-id pub-id-type="pmid">10067686</pub-id></element-citation></ref><ref id="B79-vaccines-09-01403"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vangeel</surname><given-names>I.</given-names></name><name name-style="western"><surname>Antonis</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Fluess</surname><given-names>M.</given-names></name><name name-style="western"><surname>Riegler</surname><given-names>L.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Harmeyer</surname><given-names>S.S.</given-names></name></person-group><article-title>Efficacy of a modified live intranasal bovine respiratory syncytial virus vaccine in 3-week-old calves experimentally challenged with BRSV</article-title><source>Veter. J.</source><year>2007</year><volume>174</volume><fpage>627</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1016/j.tvjl.2006.10.013</pub-id><pub-id pub-id-type="pmid">17169592</pub-id></element-citation></ref><ref id="B80-vaccines-09-01403"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mattick</surname><given-names>D.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brady</surname><given-names>R.</given-names></name><name name-style="western"><surname>Trigo</surname><given-names>E.</given-names></name></person-group><article-title>Immunogenicity of a modified-live virus vaccine against bovine viral diarrhea virus types 1 and 2, infectious bovine rhinotracheitis virus, bovine parainfluenza-3 virus, and bovine respiratory syncytial virus when administered intranasally in young calves</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>3784</fpage><lpage>3792</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.03.043</pub-id><pub-id pub-id-type="pmid">20381643</pub-id></element-citation></ref><ref id="B81-vaccines-09-01403"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chamorro</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Palomares</surname><given-names>R.A.</given-names></name></person-group><article-title>Bovine Respiratory Disease Vaccination Against Viral Pathogens: Modified-Live Versus Inactivated Antigen Vaccines, Intranasal Versus Parenteral, What Is the Evidence?</article-title><source>Veter. Clin. Food Anim.</source><year>2020</year><volume>36</volume><fpage>461</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.cvfa.2020.03.006</pub-id><pub-id pub-id-type="pmid">32451035</pub-id><pub-id pub-id-type="pmcid">PMC7244452</pub-id></element-citation></ref><ref id="B82-vaccines-09-01403"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerkhofs</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tignon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Petry</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mawhinney</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sustronck</surname><given-names>B.</given-names></name></person-group><article-title>Immune responses to bovine respiratory syncytial virus (BRSV) following use of an inactivated BRSV-PI3-Mannheimia haemolytica vaccine and a modified live BRSV&#8211;BVDV vaccine</article-title><source>Veter. J.</source><year>2004</year><volume>167</volume><fpage>208</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/S1090-0233(03)00078-9</pub-id><pub-id pub-id-type="pmid">14975397</pub-id></element-citation></ref><ref id="B83-vaccines-09-01403"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knudson</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Hartwig</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Meyerholz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Varga</surname><given-names>S.M.</given-names></name></person-group><article-title>RSV Vaccine-Enhanced Disease Is Orchestrated by the Combined Actions of Distinct CD4 T Cell Subsets</article-title><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><elocation-id>e1004757</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1004757</pub-id><pub-id pub-id-type="pmid">25769044</pub-id><pub-id pub-id-type="pmcid">PMC4358888</pub-id></element-citation></ref><ref id="B84-vaccines-09-01403"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woolums</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Singer</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Gershwin</surname><given-names>L.J.</given-names></name></person-group><article-title>Interferon gamma production during bovine respiratory syncytial virus (BRSV) infection is diminished in calves vaccinated with formalin-inactivated BRSV</article-title><source>Vaccine</source><year>1999</year><volume>17</volume><fpage>1293</fpage><lpage>1297</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(98)00379-X</pub-id><pub-id pub-id-type="pmid">10195762</pub-id></element-citation></ref><ref id="B85-vaccines-09-01403"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Demasius</surname><given-names>W.</given-names></name><name name-style="western"><surname>Weikard</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hadlich</surname><given-names>F.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>K&#252;hn</surname><given-names>C.</given-names></name></person-group><article-title>Monitoring the immune response to vaccination with an inactivated vaccine associated to bovine neonatal pancytopenia by deep sequencing transcriptome analysis in cattle</article-title><source>Veter. Res.</source><year>2013</year><volume>44</volume><fpage>93</fpage><pub-id pub-id-type="doi">10.1186/1297-9716-44-93</pub-id><pub-id pub-id-type="pmcid">PMC3851820</pub-id><pub-id pub-id-type="pmid">24099437</pub-id></element-citation></ref><ref id="B86-vaccines-09-01403"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellis</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Gow</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Mahan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leyh</surname><given-names>R.</given-names></name></person-group><article-title>Duration of immunity to experimental infection with bovine respiratory syncytial virus following intranasal vaccination of young passively immune calves</article-title><source>J. Am. Veter. Med Assoc.</source><year>2013</year><volume>243</volume><fpage>1602</fpage><lpage>1608</lpage><pub-id pub-id-type="doi">10.2460/javma.243.11.1602</pub-id><pub-id pub-id-type="pmid">24261811</pub-id></element-citation></ref><ref id="B87-vaccines-09-01403"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Didlick</surname><given-names>S.A.</given-names></name></person-group><article-title>Evaluation of efficacy of an inactivated vaccine against bovine respiratory syncytial virus in calves with maternal antibodies</article-title><source>Am. J. Veter. Res.</source><year>2004</year><volume>65</volume><fpage>417</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.2460/ajvr.2004.65.417</pub-id><pub-id pub-id-type="pmid">15077682</pub-id></element-citation></ref><ref id="B88-vaccines-09-01403"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Canchola</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Brandt</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Pyles</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chanock</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Parrott</surname><given-names>R.H.</given-names></name></person-group><article-title>Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine</article-title><source>Am. J. Epidemiol.</source><year>1968</year><volume>89</volume><fpage>422</fpage><lpage>434</lpage><comment>ISSN: 00029262</comment><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a120955</pub-id><pub-id pub-id-type="pmid">4305198</pub-id></element-citation></ref><ref id="B89-vaccines-09-01403"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonis</surname><given-names>A.F.G.</given-names></name><name name-style="western"><surname>Schrijver</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Daus</surname><given-names>F.</given-names></name><name name-style="western"><surname>Steverink</surname><given-names>P.J.G.M.</given-names></name><name name-style="western"><surname>Stockhofe</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hensen</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Langedijk</surname><given-names>J.P.M.</given-names></name><name name-style="western"><surname>van der Most</surname><given-names>R.G.</given-names></name></person-group><article-title>Vaccine-Induced Immunopathology during Bovine Respiratory Syncytial Virus Infection: Exploring the Parameters of Pathogenesis</article-title><source>J. Virol.</source><year>2003</year><volume>77</volume><fpage>12067</fpage><lpage>12073</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.22.12067-12073.2003</pub-id><pub-id pub-id-type="pmid">14581543</pub-id><pub-id pub-id-type="pmcid">PMC254282</pub-id></element-citation></ref><ref id="B90-vaccines-09-01403"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gershwin</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Schelegle</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Gunther</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Woolums</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Larochelle</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Friebertshauser</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Singer</surname><given-names>R.S.</given-names></name></person-group><article-title>A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology</article-title><source>Vaccine</source><year>1998</year><volume>16</volume><fpage>1225</fpage><lpage>1236</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(98)80123-0</pub-id><pub-id pub-id-type="pmid">9682383</pub-id></element-citation></ref><ref id="B91-vaccines-09-01403"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalina</surname><given-names>W.V.</given-names></name><name name-style="western"><surname>Woolums</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Gershwin</surname><given-names>L.J.</given-names></name></person-group><article-title>Formalin-inactivated bovine RSV vaccine influences antibody levels in bronchoalveolar lavage fluid and disease outcome in experimentally infected calves</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>4625</fpage><lpage>4630</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.04.032</pub-id><pub-id pub-id-type="pmid">15967545</pub-id></element-citation></ref><ref id="B92-vaccines-09-01403"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delgado</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Coviello</surname><given-names>S.</given-names></name><name name-style="western"><surname>Monsalvo</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>A Melendi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>J.Z.</given-names></name><name name-style="western"><surname>Batalle</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Trento</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Mitzner</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease</article-title><source>Nat. Med.</source><year>2009</year><volume>15</volume><fpage>34</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1038/nm.1894</pub-id><pub-id pub-id-type="pmid">19079256</pub-id><pub-id pub-id-type="pmcid">PMC2987729</pub-id></element-citation></ref><ref id="B93-vaccines-09-01403"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Paix&#227;o</surname><given-names>G.</given-names></name></person-group><article-title>On-farm storage of livestock vaccines may be a risk to vaccine efficacy: A study of the performance of on-farm refrigerators to maintain the correct storage temperature</article-title><source>BMC Veter. Res.</source><year>2018</year><volume>14</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1186/s12917-018-1450-z</pub-id><pub-id pub-id-type="pmcid">PMC5907741</pub-id><pub-id pub-id-type="pmid">29673345</pub-id></element-citation></ref><ref id="B94-vaccines-09-01403"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saylor</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gillam</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lohneis</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name></person-group><article-title>Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>283</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.00283</pub-id><pub-id pub-id-type="pmid">32153587</pub-id><pub-id pub-id-type="pmcid">PMC7050619</pub-id></element-citation></ref><ref id="B95-vaccines-09-01403"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C.</given-names></name></person-group><article-title>Evaluation of an outside-the-Cold-Chain Vaccine Delivery Strategy in Remote Regions of Western China</article-title><source>Public Health Rep.</source><year>2009</year><volume>124</volume><fpage>745</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1177/003335490912400517</pub-id><pub-id pub-id-type="pmid">19753953</pub-id><pub-id pub-id-type="pmcid">PMC2728668</pub-id></element-citation></ref><ref id="B96-vaccines-09-01403"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glenn</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fries</surname><given-names>L.</given-names></name><name name-style="western"><surname>Raghunandan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>B.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Hickman</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Kpamegan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Boddapati</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>524</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.11.009</pub-id><pub-id pub-id-type="pmid">23153449</pub-id></element-citation></ref><ref id="B97-vaccines-09-01403"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atuhaire</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Lieberman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Marcotty</surname><given-names>T.</given-names></name><name name-style="western"><surname>Musoke</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Madan</surname><given-names>D.</given-names></name></person-group><article-title>An alternative cold chain for storing and transporting East Coast fever vaccine</article-title><source>Veter. Parasitol.</source><year>2020</year><volume>288</volume><fpage>109304</fpage><pub-id pub-id-type="doi">10.1016/j.vetpar.2020.109304</pub-id><pub-id pub-id-type="pmid">33161281</pub-id></element-citation></ref><ref id="B98-vaccines-09-01403"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomez</surname><given-names>M.</given-names></name><name name-style="western"><surname>McCollum</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bachchhav</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tetreau</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gerhardt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Press</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Vehring</surname><given-names>R.</given-names></name></person-group><article-title>Evaluation of the stability of a spray-dried tuberculosis vaccine candidate designed for dry powder respiratory delivery</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>5025</fpage><lpage>5036</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.07.002</pub-id><pub-id pub-id-type="pmid">34256969</pub-id><pub-id pub-id-type="pmcid">PMC11702321</pub-id></element-citation></ref><ref id="B99-vaccines-09-01403"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cameron</surname><given-names>A.</given-names></name><name name-style="western"><surname>McAllister</surname><given-names>T.A.</given-names></name></person-group><article-title>Antimicrobial usage and resistance in beef production</article-title><source>J. Anim. Sci. Biotechnol.</source><year>2016</year><volume>7</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1186/s40104-016-0127-3</pub-id><pub-id pub-id-type="pmid">27999667</pub-id><pub-id pub-id-type="pmcid">PMC5154118</pub-id></element-citation></ref><ref id="B100-vaccines-09-01403"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Bryson</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>Barringer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hunsaker</surname><given-names>B.D.</given-names></name></person-group><article-title>Evaluation of on-arrival versus prompted metaphylaxis regimes using ceftiofur crystalline free acid for feedlot heifers at risk of developing bovine respiratory disease</article-title><source>Veter. Ther.</source><year>2008</year><volume>9</volume><fpage>53</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">18415947</pub-id></element-citation></ref><ref id="B101-vaccines-09-01403"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Boeckel</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Brower</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grenfell</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Levin</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Teillant</surname><given-names>A.</given-names></name><name name-style="western"><surname>Laxminarayan</surname><given-names>R.</given-names></name></person-group><article-title>Global trends in antimicrobial use in food animals</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2015</year><volume>112</volume><fpage>5649</fpage><lpage>5654</lpage><pub-id pub-id-type="doi">10.1073/pnas.1503141112</pub-id><pub-id pub-id-type="pmid">25792457</pub-id><pub-id pub-id-type="pmcid">PMC4426470</pub-id></element-citation></ref><ref id="B102-vaccines-09-01403"><label>102.</label><element-citation publication-type="gov"><person-group person-group-type="author"><collab>Department of Health</collab><collab>Department for Environment Food and Rural Affairs</collab></person-group><article-title>UK Five Year Antimicrobial Resistance Strategy: 2013 to 2018</article-title><year>2013</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf" ext-link-type="uri">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/244058/20130902_UK_5_year_AMR_strategy.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2016-07-31">(accessed on 31 July 2016)</date-in-citation></element-citation></ref><ref id="B103-vaccines-09-01403"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>S.</given-names></name></person-group><article-title>The clinical development process for a novel preventive vaccine: An overview</article-title><source>J. Postgrad. Med.</source><year>2016</year><volume>62</volume><fpage>4</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.4103/0022-3859.173187</pub-id><pub-id pub-id-type="pmid">26732191</pub-id><pub-id pub-id-type="pmcid">PMC4944327</pub-id></element-citation></ref><ref id="B104-vaccines-09-01403"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knight-Jones</surname><given-names>T.J.D.</given-names></name><name name-style="western"><surname>Edmond</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gubbins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Paton</surname><given-names>D.J.</given-names></name></person-group><article-title>Veterinary and human vaccine evaluation methods</article-title><source>Proc. R. Soc. B</source><year>2014</year><volume>281</volume><fpage>20132839</fpage><pub-id pub-id-type="doi">10.1098/rspb.2013.2839</pub-id><pub-id pub-id-type="pmcid">PMC4043076</pub-id><pub-id pub-id-type="pmid">24741009</pub-id></element-citation></ref><ref id="B105-vaccines-09-01403"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Draayer</surname><given-names>H.</given-names></name></person-group><article-title>Overview of currently approved veterinary vaccine potency testing methods and methods in development that do not require animal use</article-title><source>Procedia Vaccinol.</source><year>2011</year><volume>5</volume><fpage>171</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.provac.2011.10.016</pub-id></element-citation></ref><ref id="B106-vaccines-09-01403"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Six</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bellier</surname><given-names>B.</given-names></name><name name-style="western"><surname>Thomas-Vaslin</surname><given-names>V.</given-names></name><name name-style="western"><surname>Klatzmann</surname><given-names>D.</given-names></name></person-group><article-title>Systems biology in vaccine design</article-title><source>Microb. Biotechnol.</source><year>2012</year><volume>5</volume><fpage>295</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1111/j.1751-7915.2011.00321.x</pub-id><pub-id pub-id-type="pmid">22189033</pub-id><pub-id pub-id-type="pmcid">PMC3815789</pub-id></element-citation></ref><ref id="B107-vaccines-09-01403"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mackay</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jimenez</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Ioannou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ilott</surname><given-names>M.</given-names></name></person-group><article-title>The contribution of field efficacy studies to the evaluation of applications for veterinary vaccines evaluated through the European Union centralised authorisation procedure</article-title><source>Biologicals</source><year>2021</year><volume>70</volume><fpage>7</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2021.03.001</pub-id><pub-id pub-id-type="pmid">33840590</pub-id></element-citation></ref><ref id="B108-vaccines-09-01403"><label>108.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>The European Agency for the Evaluation of Veterinary Medicines</collab></person-group><source>Guidance for Veterinary Medicinal Products</source><gov>EMEA/CVMP/852/99-FINAL</gov><publisher-name>European Medicines Agency</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2001</year></element-citation></ref><ref id="B109-vaccines-09-01403"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levings</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>J.A.</given-names></name></person-group><article-title>Immunity to Bovine Herpesvirus 1: II. Adaptive Immunity and Vaccinology</article-title><source>Anim. Health Res. Rev.</source><year>2013</year><volume>14</volume><fpage>103</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1017/S1466252313000054</pub-id><pub-id pub-id-type="pmid">23800430</pub-id></element-citation></ref><ref id="B110-vaccines-09-01403"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guzman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>G.</given-names></name></person-group><article-title>Immunology of bovine respiratory syncytial virus in calves</article-title><source>Mol. Immunol.</source><year>2015</year><volume>66</volume><fpage>48</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2014.12.004</pub-id><pub-id pub-id-type="pmid">25553595</pub-id></element-citation></ref><ref id="B111-vaccines-09-01403"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sivakumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Safhi</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Kannadasan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sukumaran</surname><given-names>N.</given-names></name></person-group><article-title>Vaccine adjuvants &#8211; Current status and prospects on controlled release adjuvancity</article-title><source>Saudi Pharm. J.</source><year>2011</year><volume>19</volume><fpage>197</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.jsps.2011.06.003</pub-id><pub-id pub-id-type="pmid">23960760</pub-id><pub-id pub-id-type="pmcid">PMC3744968</pub-id></element-citation></ref><ref id="B112-vaccines-09-01403"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Pasquale</surname><given-names>A.</given-names></name><name name-style="western"><surname>Preiss</surname><given-names>S.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>F.M.D.O.E.</given-names></name><name name-style="western"><surname>Gar&#231;on</surname><given-names>N.</given-names></name></person-group><article-title>Vaccine Adjuvants: From 1920 to 2015 and Beyond</article-title><source>Vaccines</source><year>2015</year><volume>3</volume><fpage>320</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.3390/vaccines3020320</pub-id><pub-id pub-id-type="pmid">26343190</pub-id><pub-id pub-id-type="pmcid">PMC4494348</pub-id></element-citation></ref><ref id="B113-vaccines-09-01403"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mogil</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Crager</surname><given-names>S.E.</given-names></name></person-group><article-title>What should we be measuring in behavioral studies of chronic pain in animals?</article-title><source>Pain</source><year>2004</year><volume>112</volume><fpage>12</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2004.09.028</pub-id><pub-id pub-id-type="pmid">15494180</pub-id></element-citation></ref><ref id="B114-vaccines-09-01403"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burakova</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Madera</surname><given-names>R.</given-names></name><name name-style="western"><surname>McVey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schlup</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name></person-group><article-title>Adjuvants for Animal Vaccines</article-title><source>Viral Immunol.</source><year>2018</year><volume>31</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1089/vim.2017.0049</pub-id><pub-id pub-id-type="pmid">28618246</pub-id></element-citation></ref><ref id="B115-vaccines-09-01403"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parker</surname><given-names>R.</given-names></name><name name-style="western"><surname>Deville</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dupuis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>F.</given-names></name><name name-style="western"><surname>Aucouturier</surname><given-names>J.</given-names></name></person-group><article-title>Adjuvant formulation for veterinary vaccines: Montanide&#8482; Gel safety profile</article-title><source>Procedia Vaccinol.</source><year>2009</year><volume>1</volume><fpage>140</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.provac.2009.07.026</pub-id></element-citation></ref><ref id="B116-vaccines-09-01403"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kalaivanan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sied</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mamo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kishore</surname><given-names>S.</given-names></name><name name-style="western"><surname>Suryanarayana</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kondabattula</surname><given-names>G.</given-names></name></person-group><article-title>Montanide ISA&#8482; 201 adjuvanted FMD vaccine induces improved immune responses and protection in cattle</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>3327</fpage><lpage>3332</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.05.078</pub-id><pub-id pub-id-type="pmid">23735678</pub-id></element-citation></ref><ref id="B117-vaccines-09-01403"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vishanath</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Dechamma</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Ganesh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Suryanarayana</surname><given-names>V.V.S.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>G.R.</given-names></name></person-group><article-title>DNA vaccine (P1-2A-3C-pCDNA) co-administered with Bovine IL-18 gives protective immune response against Foot and Mouth Disease in cattle</article-title><source>Veter. Microbiol.</source><year>2016</year><volume>193</volume><fpage>106</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2016.07.007</pub-id><pub-id pub-id-type="pmid">27599937</pub-id></element-citation></ref><ref id="B118-vaccines-09-01403"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson-Welder</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Boggiatto</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nally</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Wafa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Alt</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Hornsby</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Frank</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Bowden</surname><given-names>N.B.</given-names></name><etal/></person-group><article-title>Bovine immune response to leptospira antigen in different novel adjuvants and vaccine delivery platforms</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>3464</fpage><lpage>3473</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.02.086</pub-id><pub-id pub-id-type="pmid">32204939</pub-id></element-citation></ref><ref id="B119-vaccines-09-01403"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gon&#231;alves</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>F.D.S.</given-names></name><name name-style="western"><surname>Junior</surname><given-names>A.G.D.S.</given-names></name><name name-style="western"><surname>Piraine</surname><given-names>R.E.A.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>P.R.C.</given-names></name><name name-style="western"><surname>Brasil</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Conrad</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Leite</surname><given-names>F.P.L.</given-names></name></person-group><article-title>Recombinant bovine IL17A acts as an adjuvant for bovine herpesvirus vaccine</article-title><source>Res. Veter. Sci.</source><year>2021</year><volume>136</volume><fpage>185</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.rvsc.2021.02.014</pub-id><pub-id pub-id-type="pmid">33677208</pub-id></element-citation></ref><ref id="B120-vaccines-09-01403"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carine</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mathieu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Laurent</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jean-Fran&#231;ois</surname><given-names>T.</given-names></name><name name-style="western"><surname>Karl</surname><given-names>W.</given-names></name><name name-style="western"><surname>Stefan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gilles</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jean-Jacques</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pierre</surname><given-names>K.</given-names></name><name name-style="western"><surname>Letellier</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Vaccination of calves using the BRSV nucleocapsid protein in a DNA prime&#8211;protein boost strategy stimulates cell-mediated immunity and protects the lungs against BRSV replication and pathology</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>4840</fpage><lpage>4848</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.06.100</pub-id><pub-id pub-id-type="pmid">18644416</pub-id><pub-id pub-id-type="pmcid">PMC7115630</pub-id></element-citation></ref><ref id="B121-vaccines-09-01403"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>K.</given-names></name><name name-style="western"><surname>Arsic</surname><given-names>N.</given-names></name><name name-style="western"><surname>Nordstrom</surname><given-names>S.</given-names></name><name name-style="western"><surname>Griebel</surname><given-names>P.J.</given-names></name></person-group><article-title>Immune memory induced by intranasal vaccination with a modified-live viral vaccine delivered to colostrum fed neonatal calves</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>7455</fpage><lpage>7462</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.09.080</pub-id><pub-id pub-id-type="pmid">31590936</pub-id></element-citation></ref><ref id="B122-vaccines-09-01403"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name></person-group><article-title>Heterologous prime-boost vaccination</article-title><source>Curr. Opin. Immun.</source><year>2009</year><volume>21</volume><fpage>346</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2009.05.016</pub-id><pub-id pub-id-type="pmcid">PMC3743086</pub-id><pub-id pub-id-type="pmid">19500964</pub-id></element-citation></ref><ref id="B123-vaccines-09-01403"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kardani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bolhassani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shahbazi</surname><given-names>S.</given-names></name></person-group><article-title>Prime-boost vaccine strategy against viral infections: Mechanisms and benefits</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>413</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.11.062</pub-id><pub-id pub-id-type="pmid">26691569</pub-id></element-citation></ref><ref id="B124-vaccines-09-01403"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mapletoft</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Latimer</surname><given-names>L.</given-names></name><name name-style="western"><surname>Babiuk</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Hurk</surname><given-names>S.V.D.L.-V.D.</given-names></name></person-group><article-title>Intranasal Immunization of Mice with a Bovine Respiratory Syncytial Virus Vaccine Induces Superior Immunity and Protection Compared to Those by Subcutaneous Delivery or Combinations of Intranasal and Subcutaneous Prime-Boost Strategies</article-title><source>Clin. Vaccine Immunol.</source><year>2010</year><volume>17</volume><fpage>23</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1128/CVI.00250-09</pub-id><pub-id pub-id-type="pmid">19864487</pub-id><pub-id pub-id-type="pmcid">PMC2812083</pub-id></element-citation></ref><ref id="B125-vaccines-09-01403"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Woolums</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Zarlenga</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>M.A.</given-names></name></person-group><article-title>Effects of a single intranasal dose of modified-live bovine respiratory syncytial virus vaccine on cytokine messenger RNA expression following viral challenge in calves</article-title><source>Am. J. Veter. Res.</source><year>2004</year><volume>65</volume><fpage>725</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.2460/ajvr.2004.65.725</pub-id><pub-id pub-id-type="pmid">15198210</pub-id></element-citation></ref><ref id="B126-vaccines-09-01403"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riffault</surname><given-names>S.</given-names></name><name name-style="western"><surname>H&#228;gglund</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>E.</given-names></name><name name-style="western"><surname>N&#228;slund</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jouneau</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dubuquoy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Valarcher</surname><given-names>J.F.</given-names></name></person-group><article-title>A Single Shot Pre-fusion-Stabilized Bovine RSV F Vaccine is Safe and E ff ective in Newborn Calves with Maternally Derived Antibodies</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>231</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8020231</pub-id><pub-id pub-id-type="pmid">32443437</pub-id><pub-id pub-id-type="pmcid">PMC7349975</pub-id></element-citation></ref><ref id="B127-vaccines-09-01403"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mawhinney</surname><given-names>I.C.</given-names></name><name name-style="western"><surname>Burrows</surname><given-names>M.R.</given-names></name></person-group><article-title>Protection against bovine respiratory syncytial virus challenge following a single dose of vaccine in young calves with maternal antibody</article-title><source>Veter. Rec.</source><year>2005</year><volume>156</volume><fpage>139</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1136/vr.156.5.139</pub-id><pub-id pub-id-type="pmid">15715005</pub-id></element-citation></ref><ref id="B128-vaccines-09-01403"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loucks</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Morrill</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Dayton</surname><given-names>A.D.</given-names></name></person-group><article-title>Effect of prepartum vaccination with K99 <italic toggle="yes">Esherichia coli</italic> vaccine on maternal and calf blood antibody concentration and calf health</article-title><source>J. Dairy Sci.</source><year>1985</year><volume>68</volume><fpage>1841</fpage><lpage>1847</lpage><pub-id pub-id-type="doi">10.3168/jds.S0022-0302(85)81037-7</pub-id><pub-id pub-id-type="pmid">3897306</pub-id></element-citation></ref><ref id="B129-vaccines-09-01403"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kohara</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hirai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ishizaki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tsunemitsu</surname><given-names>H.</given-names></name></person-group><article-title>Enhancement of Passive Immunity with Maternal Vaccine against Newborn Calf Diarrhea</article-title><source>J. Veter. Med Sci.</source><year>1997</year><volume>59</volume><fpage>1023</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1292/jvms.59.1023</pub-id><pub-id pub-id-type="pmid">9409518</pub-id></element-citation></ref><ref id="B130-vaccines-09-01403"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dudek</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bednarek</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ayling</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Szacawa</surname><given-names>E.</given-names></name></person-group><article-title>Stimulation and analysis of the immune response in calves from vaccinated pregnant cows</article-title><source>Res. Veter.Sci.</source><year>2014</year><volume>97</volume><fpage>32</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.rvsc.2014.04.005</pub-id><pub-id pub-id-type="pmid">24815344</pub-id><pub-id pub-id-type="pmcid">PMC7126404</pub-id></element-citation></ref><ref id="B131-vaccines-09-01403"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baccili</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Baldacim</surname><given-names>P.</given-names></name><name name-style="western"><surname>Greghi</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Vasconcellos</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Cacciacarro</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>V.</given-names></name></person-group><article-title>Influence of maternal vaccination for the passive immune transfer against bovine respiratory viruses</article-title><source>Arq. Bras. Med. Veterin&#225;ria Zootec.</source><year>2018</year><volume>70</volume><fpage>391</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1590/1678-4162-9496</pub-id></element-citation></ref><ref id="B132-vaccines-09-01403"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tardon</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Allard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dutoit</surname><given-names>V.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>P.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>P.R.</given-names></name></person-group><article-title>Peptides as cancer vaccines</article-title><source>Curr. Opin. Pharmacol.</source><year>2019</year><volume>47</volume><fpage>20</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2019.01.007</pub-id><pub-id pub-id-type="pmid">30831470</pub-id></element-citation></ref><ref id="B133-vaccines-09-01403"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Combadi&#232;re</surname><given-names>B.</given-names></name><name name-style="western"><surname>Beaujean</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chaudesaigues</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vieillard</surname><given-names>V.</given-names></name></person-group><article-title>Peptide-Based Vaccination for Antibody Responses Against HIV</article-title><source>Vaccines</source><year>2019</year><volume>7</volume><elocation-id>105</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines7030105</pub-id><pub-id pub-id-type="pmid">31480779</pub-id><pub-id pub-id-type="pmcid">PMC6789779</pub-id></element-citation></ref><ref id="B134-vaccines-09-01403"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakagami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Koriyama</surname><given-names>H.</given-names></name><name name-style="western"><surname>Morishita</surname><given-names>R.</given-names></name></person-group><article-title>Peptide Vaccines for Hypertension and Diabetes Mellitus</article-title><source>Vaccines</source><year>2014</year><volume>2</volume><fpage>832</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.3390/vaccines2040832</pub-id><pub-id pub-id-type="pmid">26344893</pub-id><pub-id pub-id-type="pmcid">PMC4494253</pub-id></element-citation></ref><ref id="B135-vaccines-09-01403"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Belsham</surname><given-names>G.J.</given-names></name></person-group><article-title>Towards improvements in foot-and-mouth disease vaccine performance</article-title><source>Acta Veter. Scand.</source><year>2020</year><volume>62</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/s13028-020-00519-1</pub-id><pub-id pub-id-type="pmcid">PMC7240906</pub-id><pub-id pub-id-type="pmid">32434544</pub-id></element-citation></ref><ref id="B136-vaccines-09-01403"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paarlberg</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Seitzinger</surname><given-names>A.H.</given-names></name></person-group><article-title>Potential revenue impact of an outbreak of foot-and-mouth disease in the United States</article-title><source>J. Am. Veter. Med Assoc.</source><year>2002</year><volume>220</volume><fpage>988</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.2460/javma.2002.220.988</pub-id><pub-id pub-id-type="pmid">12420775</pub-id></element-citation></ref><ref id="B137-vaccines-09-01403"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenwood</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Dynon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kalkanidis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Plebanski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scheerlinck</surname><given-names>J.-P.Y.</given-names></name></person-group><article-title>Vaccination against foot-and-mouth disease virus using peptides conjugated to nano-beads</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>2706</fpage><lpage>2713</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.03.025</pub-id><pub-id pub-id-type="pmid">18448209</pub-id></element-citation></ref><ref id="B138-vaccines-09-01403"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Walfield</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Jong</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P.C.</given-names></name><etal/></person-group><article-title>Effective synthetic peptide vaccine for foot-and-mouth disease in swine</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><fpage>2603</fpage><lpage>2610</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00148-2</pub-id><pub-id pub-id-type="pmid">12057619</pub-id></element-citation></ref><ref id="B139-vaccines-09-01403"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Efficacy of synthetic peptide candidate vaccines against serotype-A foot-and-mouth disease virus in cattle</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2015</year><volume>99</volume><fpage>1389</fpage><lpage>1398</lpage><pub-id pub-id-type="doi">10.1007/s00253-014-6129-1</pub-id><pub-id pub-id-type="pmid">25381487</pub-id></element-citation></ref><ref id="B140-vaccines-09-01403"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bastien</surname><given-names>N.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>G.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Wyld</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Simard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Trudel</surname><given-names>M.</given-names></name></person-group><article-title>Immunization with a peptide derived from the G glycoprotein of bovine respiratory syncytial virus (BRSV) reduces the incidence of BRSV-associated pneumonia in the natural host</article-title><source>Vaccine</source><year>1997</year><volume>15</volume><fpage>1385</fpage><lpage>1390</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(97)00033-9</pub-id><pub-id pub-id-type="pmid">9302749</pub-id></element-citation></ref><ref id="B141-vaccines-09-01403"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trudel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nadon</surname><given-names>F.</given-names></name><name name-style="western"><surname>S&#233;guin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Binz</surname><given-names>H.</given-names></name></person-group><article-title>Protection of BALE/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein</article-title><source>Virology</source><year>1991</year><volume>185</volume><fpage>749</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(91)90546-N</pub-id><pub-id pub-id-type="pmid">1720589</pub-id></element-citation></ref><ref id="B142-vaccines-09-01403"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Power</surname><given-names>U.</given-names></name><name name-style="western"><surname>Plotnicky-Gilquin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huss</surname><given-names>T.</given-names></name><name name-style="western"><surname>Robert</surname><given-names>A.</given-names></name><name name-style="western"><surname>Trudel</surname><given-names>M.</given-names></name><name name-style="western"><surname>St&#229;hl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Uhl&#233;n</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Binz</surname><given-names>H.</given-names></name></person-group><article-title>Induction of Protective Immunity in Rodents by Vaccination with a Prokaryotically Expressed Recombinant Fusion Protein Containing a Respiratory Syncytial Virus G Protein Fragment</article-title><source>Virology</source><year>1997</year><volume>230</volume><fpage>155</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1006/viro.1997.8465</pub-id><pub-id pub-id-type="pmid">9143271</pub-id></element-citation></ref><ref id="B143-vaccines-09-01403"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaberolansar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Watterson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bermingham</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>I.</given-names></name><name name-style="western"><surname>Young</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Skwarczynski</surname><given-names>M.</given-names></name></person-group><article-title>Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/s41598-017-10415-w</pub-id><pub-id pub-id-type="pmid">28894111</pub-id><pub-id pub-id-type="pmcid">PMC5593926</pub-id></element-citation></ref><ref id="B144-vaccines-09-01403"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trudel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nadon</surname><given-names>F.</given-names></name><name name-style="western"><surname>S&#233;guin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Simard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lussier</surname><given-names>G.</given-names></name></person-group><article-title>Experimental polyvalent ISCOMs subunit vaccine induces antibodies that neutralize human and bovine respiratory syncytial virus</article-title><source>Vaccine</source><year>1989</year><volume>7</volume><fpage>12</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(89)90004-2</pub-id><pub-id pub-id-type="pmid">2718604</pub-id></element-citation></ref><ref id="B145-vaccines-09-01403"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#228;gglund</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Vargmar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Por&#233;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Olofson</surname><given-names>A.-S.</given-names></name><name name-style="western"><surname>Blod&#246;rn</surname><given-names>K.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ahooghalandari</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pringle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Bovine respiratory syncytial virus ISCOMs&#8212;Immunity, protection and safety in young conventional calves</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>8719</fpage><lpage>8730</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.07.146</pub-id><pub-id pub-id-type="pmid">21864616</pub-id><pub-id pub-id-type="pmcid">PMC7115641</pub-id></element-citation></ref><ref id="B146-vaccines-09-01403"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Franz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hampl</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stepanek</surname><given-names>J.</given-names></name><name name-style="western"><surname>&#348;mid</surname><given-names>B.</given-names></name></person-group><article-title>Preparation of Immunostimulating Complexes (ISCOM) Containing Bovine Herpesvirus 1 Proteins</article-title><source>Acta Veter. Brno</source><year>1992</year><volume>61</volume><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.2754/avb199261010037</pub-id></element-citation></ref><ref id="B147-vaccines-09-01403"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamstrup</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roensholt</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dalsgaard</surname><given-names>K.</given-names></name></person-group><article-title>Production of a highly immunogenic subunit ISCOM vaccine against Bovine Viral Diarrhea Virus</article-title><source>Vaccine</source><year>1999</year><volume>17</volume><fpage>1057</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(98)00322-3</pub-id><pub-id pub-id-type="pmid">10195615</pub-id></element-citation></ref><ref id="B148-vaccines-09-01403"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crisci</surname><given-names>E.</given-names></name><name name-style="western"><surname>B&#225;rcena</surname><given-names>J.</given-names></name><name name-style="western"><surname>Montoya</surname><given-names>M.</given-names></name></person-group><article-title>Virus-like particles: The new frontier of vaccines for animal viral infections</article-title><source>Veter. Immunol. Immunopathol.</source><year>2012</year><volume>148</volume><fpage>211</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.vetimm.2012.04.026</pub-id><pub-id pub-id-type="pmid">22705417</pub-id><pub-id pub-id-type="pmcid">PMC7112581</pub-id></element-citation></ref><ref id="B149-vaccines-09-01403"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loy</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Gander</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mogler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Veen</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Ridpath</surname><given-names>J.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Kamrud</surname><given-names>K.</given-names></name></person-group><article-title>Development and evaluation of a replicon particle vaccine expressing the E2 glycoprotein of bovine viral diarrhea virus (BVDV) in cattle</article-title><source>Virol. J.</source><year>2013</year><volume>10</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-10-35</pub-id><pub-id pub-id-type="pmid">23356714</pub-id><pub-id pub-id-type="pmcid">PMC3565941</pub-id></element-citation></ref><ref id="B150-vaccines-09-01403"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zolnik</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Fern&#225;ndez</surname><given-names>&#193;.</given-names></name><name name-style="western"><surname>Sadrieh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dobrovolskaia</surname><given-names>M.A.</given-names></name></person-group><article-title>Minireview: Nanoparticles and the Immune System</article-title><source>Endocrinology</source><year>2010</year><volume>151</volume><fpage>458</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1210/en.2009-1082</pub-id><pub-id pub-id-type="pmid">20016026</pub-id><pub-id pub-id-type="pmcid">PMC2817614</pub-id></element-citation></ref><ref id="B151-vaccines-09-01403"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansoor</surname><given-names>F.</given-names></name><name name-style="western"><surname>Earley</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cassidy</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Markey</surname><given-names>B.</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>M.D.</given-names></name></person-group><article-title>Comparing the immune response to a novel intranasal nanoparticle PLGA vaccine and a commercial BPI3V vaccine in dairy calves</article-title><source>BMC Veter. Res.</source><year>2015</year><volume>11</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1186/s12917-015-0481-y</pub-id><pub-id pub-id-type="pmid">26293453</pub-id><pub-id pub-id-type="pmcid">PMC4546173</pub-id></element-citation></ref><ref id="B152-vaccines-09-01403"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kavanagh</surname><given-names>O.V.</given-names></name><name name-style="western"><surname>Adair</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Earley</surname><given-names>B.</given-names></name></person-group><article-title>Immunogenetic responses in calves to intranasal delivery of bovine respiratory syncytial virus (BRSV) epitopes encapsulated in poly (DL-lactide-co-glycolide) microparticles</article-title><source>Res. Veter. Sci.</source><year>2013</year><volume>95</volume><fpage>786</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1016/j.rvsc.2013.06.023</pub-id><pub-id pub-id-type="pmid">23890818</pub-id></element-citation></ref><ref id="B153-vaccines-09-01403"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cerbu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kah</surname><given-names>M.</given-names></name><name name-style="western"><surname>White</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Astete</surname><given-names>C.E.</given-names></name></person-group><article-title>Fate of Biodegradable Engineered Nanoparticles Used in Health Perspective</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>523</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26030523</pub-id><pub-id pub-id-type="pmid">33498295</pub-id><pub-id pub-id-type="pmcid">PMC7863917</pub-id></element-citation></ref><ref id="B154-vaccines-09-01403"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mahendran</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Rai</surname><given-names>A.</given-names></name></person-group><article-title>DNA vaccines and their applications in veterinary practice: Current perspectives</article-title><source>Veter. Res. Commun.</source><year>2008</year><volume>32</volume><fpage>341</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1007/s11259-008-9040-3</pub-id><pub-id pub-id-type="pmcid">PMC7089108</pub-id><pub-id pub-id-type="pmid">18425596</pub-id></element-citation></ref><ref id="B155-vaccines-09-01403"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oshop</surname><given-names>G.</given-names></name><name name-style="western"><surname>Elankumaran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Heckert</surname><given-names>R.</given-names></name></person-group><article-title>DNA vaccination in the avian</article-title><source>Veter. Immunol. Immunopathol.</source><year>2002</year><volume>89</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/S0165-2427(02)00189-7</pub-id><pub-id pub-id-type="pmid">12208046</pub-id></element-citation></ref><ref id="B156-vaccines-09-01403"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunham</surname><given-names>S.P.</given-names></name></person-group><article-title>The application of nucleic acid vaccines in veterinary medicine</article-title><source>Res. Veter. Sci.</source><year>2002</year><volume>73</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/S0034-5288(02)00032-2</pub-id><pub-id pub-id-type="pmid">12208102</pub-id></element-citation></ref><ref id="B157-vaccines-09-01403"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patial</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chaturvedi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rai</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Saini</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>P.K.</given-names></name></person-group><article-title>Virus neutralizing antibody response in mice and dogs with a bicistronic DNA vaccine encoding rabies virus glycoprotein and canine parvovirus VP2</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>4020</fpage><lpage>4028</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.02.051</pub-id><pub-id pub-id-type="pmid">17391817</pub-id></element-citation></ref><ref id="B158-vaccines-09-01403"><label>158.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Babiuk</surname><given-names>S.</given-names></name><name name-style="western"><surname>Babiuk</surname><given-names>L.A.</given-names></name></person-group><article-title>DNA vaccines</article-title><source>Encyclopedia of Virology</source><edition>3rd ed.</edition><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2008</year><fpage>51</fpage><lpage>55</lpage></element-citation></ref><ref id="B159-vaccines-09-01403"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nobiron</surname><given-names>I.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>I.</given-names></name><name name-style="western"><surname>Brownlie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>M.E.</given-names></name></person-group><article-title>DNA vaccination against bovine viral diarrhoea virus induces humoral and cellular responses in cattle with evidence for protection against viral challenge</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><fpage>2082</fpage><lpage>2092</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00745-4</pub-id><pub-id pub-id-type="pmid">12706698</pub-id></element-citation></ref><ref id="B160-vaccines-09-01403"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulmer</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Felgner</surname><given-names>P.L.</given-names></name><name name-style="western"><surname>Dwarki</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.A.</given-names></name></person-group><article-title>Heterolgous protection against influenza by injection of DNA encoding a viral protein</article-title><source>Science</source><year>1993</year><volume>259</volume><fpage>1745</fpage><lpage>1749</lpage><pub-id pub-id-type="doi">10.1126/science.8456302</pub-id><pub-id pub-id-type="pmid">8456302</pub-id></element-citation></ref><ref id="B161-vaccines-09-01403"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamers</surname><given-names>C.</given-names></name><name name-style="western"><surname>Juillard</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>L.</given-names></name></person-group><article-title>DNA Vaccination against Pseudorabies Virus and Bovine Respiratory Syncytial Virus Infections of Young Animals in the Face of Maternally Derived Immunity</article-title><source>J. Comp. Pathol.</source><year>2007</year><volume>137</volume><fpage>S35</fpage><lpage>S41</lpage><pub-id pub-id-type="doi">10.1016/j.jcpa.2007.04.010</pub-id><pub-id pub-id-type="pmid">17553517</pub-id></element-citation></ref><ref id="B162-vaccines-09-01403"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>C.</given-names></name><name name-style="western"><surname>Barbet</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Wyld</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>L.H.</given-names></name></person-group><article-title>DNA vaccination against respiratory syncytial virus in young calves</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>1242</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.09.005</pub-id><pub-id pub-id-type="pmid">15652666</pub-id></element-citation></ref><ref id="B163-vaccines-09-01403"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schrijver</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Langedijk</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Keil</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Middel</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Maris-Veldhuis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Van Oirschot</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>A Rijsewijk</surname><given-names>F.</given-names></name></person-group><article-title>Immunization of cattle with a BHV1 vector vaccine or a DNA vaccine both coding for the G protein of BRSV</article-title><source>Vaccine</source><year>1997</year><volume>15</volume><fpage>1908</fpage><lpage>1916</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(97)00129-1</pub-id><pub-id pub-id-type="pmid">9413101</pub-id></element-citation></ref><ref id="B164-vaccines-09-01403"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kornuta</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Langellotti</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Bidart</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Soria</surname><given-names>I.</given-names></name><name name-style="western"><surname>Quattrocchi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gammella</surname><given-names>M.</given-names></name><name name-style="western"><surname>Valenzuela</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Mignaqui</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Ferraris</surname><given-names>S.</given-names></name><name name-style="western"><surname>Charleston</surname><given-names>B.</given-names></name><etal/></person-group><article-title>A plasmid encoding the extracellular domain of CD40 ligand and Montanide&#8482; GEL01 as adjuvants enhance the immunogenicity and the protection induced by a DNA vaccine against BoHV-1</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><fpage>1007</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.11.071</pub-id><pub-id pub-id-type="pmid">33446386</pub-id></element-citation></ref><ref id="B165-vaccines-09-01403"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Redding</surname><given-names>L.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>D.B.</given-names></name></person-group><article-title>DNA vaccines in veterinary use</article-title><source>Expert Rev. Vaccines</source><year>2009</year><volume>8</volume><fpage>1251</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1586/erv.09.77</pub-id><pub-id pub-id-type="pmid">19722897</pub-id><pub-id pub-id-type="pmcid">PMC4425421</pub-id></element-citation></ref><ref id="B166-vaccines-09-01403"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>N.A.C.</given-names></name><name name-style="western"><surname>Kester</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Casimiro</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gurunathan</surname><given-names>S.</given-names></name><name name-style="western"><surname>DeRosa</surname><given-names>F.</given-names></name></person-group><article-title>The promise of mRNA vaccines: A biotech and industrial perspective</article-title><source>npj Vaccines</source><year>2020</year><volume>5</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/s41541-020-0159-8</pub-id><pub-id pub-id-type="pmid">32047656</pub-id><pub-id pub-id-type="pmcid">PMC7000814</pub-id></element-citation></ref><ref id="B167-vaccines-09-01403"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dolgin</surname><given-names>E.</given-names></name></person-group><article-title>The tangled history of mRNA vaccines</article-title><source>Nature</source><year>2021</year><volume>597</volume><fpage>318</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1038/d41586-021-02483-w</pub-id><pub-id pub-id-type="pmid">34522017</pub-id></element-citation></ref><ref id="B168-vaccines-09-01403"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pelc</surname><given-names>R.</given-names></name><name name-style="western"><surname>Muramatsu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>H.</given-names></name><name name-style="western"><surname>DeMaso</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Dowd</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Sutherland</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Scearce</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Parks</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination</article-title><source>Nature</source><year>2017</year><volume>543</volume><fpage>248</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1038/nature21428</pub-id><pub-id pub-id-type="pmid">28151488</pub-id><pub-id pub-id-type="pmcid">PMC5344708</pub-id></element-citation></ref><ref id="B169-vaccines-09-01403"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petsch</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schnee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lange</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Voss</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schlake</surname><given-names>T.</given-names></name><name name-style="western"><surname>Thess</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kallen</surname><given-names>K.-J.</given-names></name><name name-style="western"><surname>Stitz</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection</article-title><source>Nat. Biotechnol.</source><year>2012</year><volume>30</volume><fpage>1210</fpage><lpage>1216</lpage><pub-id pub-id-type="doi">10.1038/nbt.2436</pub-id><pub-id pub-id-type="pmid">23159882</pub-id></element-citation></ref><ref id="B170-vaccines-09-01403"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alberer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gnad-Vogt</surname><given-names>U.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Mehr</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Backert</surname><given-names>L.</given-names></name><name name-style="western"><surname>Finak</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gottardo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bica</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Garofano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>S.D.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: An open-label, non-randomised, prospective, first-in-human phase 1 clinical trial</article-title><source>Lancet</source><year>2017</year><volume>390</volume><fpage>1511</fpage><lpage>1520</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(17)31665-3</pub-id><pub-id pub-id-type="pmid">28754494</pub-id></element-citation></ref><ref id="B171-vaccines-09-01403"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batra</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Shanthalingam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Donofrio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Haldorson</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>S.</given-names></name><name name-style="western"><surname>White</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Srikumaran</surname><given-names>S.</given-names></name></person-group><article-title>Immunization of bighorn sheep against Mannheimia haemolytica with a bovine herpesvirus 1-vectored vaccine</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>1630</fpage><lpage>1636</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2017.02.006</pub-id><pub-id pub-id-type="pmid">28228321</pub-id></element-citation></ref><ref id="B172-vaccines-09-01403"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bilge</surname><given-names>S.</given-names></name><name name-style="western"><surname>Touraj</surname><given-names>D.</given-names></name><name name-style="western"><surname>Farzani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dogan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Akkutay</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Aykut</surname><given-names>Y.</given-names></name></person-group><article-title>Development of a BoHV&#8212;4 viral vector expressing tgD of BoHV&#8212;1 and evaluation of its immunogenicity in mouse model</article-title><source>Braz. J. Microbiol.</source><year>2021</year><volume>52</volume><fpage>1119</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1007/s42770-021-00525-z</pub-id><pub-id pub-id-type="pmid">34255309</pub-id><pub-id pub-id-type="pmcid">PMC8275906</pub-id></element-citation></ref><ref id="B173-vaccines-09-01403"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chowdhury</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Pannhorst</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sangewar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pavulraj</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Stout</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Mwangi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Paulsen</surname><given-names>D.B.</given-names></name></person-group><article-title>BoHV-1-Vectored BVDV-2 Subunit Vaccine Induces BVDV Cross-Reactive Cellular Immune Responses and Protects against BVDV-2 Challenge</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>46</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9010046</pub-id><pub-id pub-id-type="pmid">33451136</pub-id><pub-id pub-id-type="pmcid">PMC7828602</pub-id></element-citation></ref><ref id="B174-vaccines-09-01403"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>G.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Wyld</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Wertz</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Hardy</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Furze</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Lerch</surname><given-names>R.</given-names></name></person-group><article-title>Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of bovine respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions</article-title><source>J. Gen. Virol.</source><year>1997</year><volume>78</volume><fpage>3195</fpage><lpage>3206</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-78-12-3195</pub-id><pub-id pub-id-type="pmid">9400970</pub-id></element-citation></ref><ref id="B175-vaccines-09-01403"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonis</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>van der Most</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Suezer</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Stockhofe-Zurwieden</surname><given-names>N.</given-names></name><name name-style="western"><surname>Daus</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sutter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schrijver</surname><given-names>R.S.</given-names></name></person-group><article-title>Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>4818</fpage><lpage>4827</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.04.002</pub-id><pub-id pub-id-type="pmid">17499893</pub-id></element-citation></ref><ref id="B176-vaccines-09-01403"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nelson</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marconi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Periolo</surname><given-names>O.</given-names></name><name name-style="western"><surname>La Torre</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>M.A.</given-names></name></person-group><article-title>Immunocompetent truncated E2 glycoprotein of bovine viral diarrhea virus (BVDV) expressed in Nicotiana tabacum plants: A candidate antigen for new generation of veterinary vaccines</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>4499</fpage><lpage>4504</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.04.068</pub-id><pub-id pub-id-type="pmid">22554468</pub-id></element-citation></ref><ref id="B177-vaccines-09-01403"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faye</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gomord</surname><given-names>V.</given-names></name></person-group><article-title>Editorial Success stories in molecular farming&#8212;A brief overview</article-title><source>Plant Biotechnol. J.</source><year>2010</year><volume>8</volume><fpage>525</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1111/j.1467-7652.2010.00521.x</pub-id><pub-id pub-id-type="pmid">20500680</pub-id></element-citation></ref><ref id="B178-vaccines-09-01403"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rybicki</surname><given-names>E.P.</given-names></name></person-group><article-title>Plant-made vaccines for humans and animals</article-title><source>Plant Biotechnol. J.</source><year>2010</year><volume>8</volume><fpage>620</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1111/j.1467-7652.2010.00507.x</pub-id><pub-id pub-id-type="pmid">20233333</pub-id><pub-id pub-id-type="pmcid">PMC7167690</pub-id></element-citation></ref><ref id="B179-vaccines-09-01403"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wyld</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Keil</surname><given-names>G.</given-names></name><name name-style="western"><surname>I Morrison</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hensen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cook</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>A Rijsewijk</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gaddum</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Van Oirschot</surname><given-names>J.T.</given-names></name></person-group><article-title>Resistance to bovine respiratory syncytial virus (BRSV) induced in calves by a recombinant bovine herpesvirus-1 expressing the attachment glycoprotein of BRSV</article-title><source>J. Gen. Virol.</source><year>1998</year><volume>79</volume><fpage>1759</fpage><lpage>1767</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-79-7-1759</pub-id><pub-id pub-id-type="pmid">9680140</pub-id></element-citation></ref><ref id="B180-vaccines-09-01403"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Briggs</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Tabatabai</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Tatum</surname><given-names>F.M.</given-names></name></person-group><article-title>Microbial Pathogenesis Mucosal and parenteral vaccination against pneumonic pasteurellosis in cattle with a modi fi ed-live in-frame lktA deletion mutant of Mannheimia haemolytica</article-title><source>Microb. Pathog.</source><year>2012</year><volume>52</volume><fpage>302</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2012.02.008</pub-id><pub-id pub-id-type="pmid">22401911</pub-id></element-citation></ref><ref id="B181-vaccines-09-01403"><label>181.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>AFBI/DAERA</collab></person-group><source>All-Island Disease Surveillance Report: A Joint AFBI/DAFM Veterinary Laboratories Report</source><publisher-name>AFBI</publisher-name><publisher-loc>Belfast, UK</publisher-loc><year>2016</year></element-citation></ref><ref id="B182-vaccines-09-01403"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pretty</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sutherland</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Ashby</surname><given-names>J.</given-names></name><name name-style="western"><surname>Auburn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baulcombe</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bentley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bickersteth</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>J.</given-names></name><etal/></person-group><article-title>The top 100 questions of importance to the future of global agriculture</article-title><source>Int. J. Agric. Sustain.</source><year>2010</year><volume>8</volume><fpage>219</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.3763/ijas.2010.0534</pub-id></element-citation></ref><ref id="B183-vaccines-09-01403"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daly</surname><given-names>P.A.</given-names></name></person-group><article-title>Agricultural employment: Has the decline ended?</article-title><source>Mon. Labor Rev.</source><year>1981</year><volume>104</volume><fpage>11</fpage><lpage>17</lpage></element-citation></ref><ref id="B184-vaccines-09-01403"><label>184.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Roser</surname><given-names>M.</given-names></name></person-group><article-title>Employment in agriculture. Our World in Data</article-title><year>2013</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ourworldindata.org/employment-in-agriculture" ext-link-type="uri">https://ourworldindata.org/employment-in-agriculture</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-09-27">(accessed on 27 September 2021)</date-in-citation></element-citation></ref><ref id="B185-vaccines-09-01403"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>U.</given-names></name><name name-style="western"><surname>Havl&#237;k</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>E.</given-names></name><name name-style="western"><surname>Valin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mosnier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Obersteiner</surname><given-names>M.</given-names></name><name name-style="western"><surname>B&#246;ttcher</surname><given-names>H.</given-names></name><name name-style="western"><surname>Skalsk&#253;</surname><given-names>R.</given-names></name><name name-style="western"><surname>Balkovi&#269;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sauer</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Impacts of population growth, economic development, and technical change on global food production and consumption</article-title><source>Agric. Syst.</source><year>2011</year><volume>104</volume><fpage>204</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/j.agsy.2010.11.003</pub-id></element-citation></ref><ref id="B186-vaccines-09-01403"><label>186.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Department for Environment Food and Rural Affairs</collab></person-group><source>Total Income from Farming in the United Kingdom, First Estimate for 2020</source><publisher-name>Department for Environment Food and Rural Affairs</publisher-name><publisher-loc>Bristol, UK</publisher-loc><year>2021</year></element-citation></ref><ref id="B187-vaccines-09-01403"><label>187.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>M.</given-names></name></person-group><article-title>Northern Ireland&#8217;s Agri-Food Sector&#8212;Background and possible &#8216;Brexit&#8217; Considerations</article-title><year>2016</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.niassembly.gov.uk/globalassets/documents/raise/publications/2016-2021/2016/aera/6616.pdf" ext-link-type="uri">http://www.niassembly.gov.uk/globalassets/documents/raise/publications/2016-2021/2016/aera/6616.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2017-07-16">(accessed on 16 July 2017)</date-in-citation></element-citation></ref><ref id="B188-vaccines-09-01403"><label>188.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Playfair</surname><given-names>D.</given-names></name></person-group><article-title>Northern Ireland Agri-Food Sector&#8212;Agriculture, Fishing and Forestry</article-title><year>2018</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.daera-ni.gov.uk/sites/default/files/publications/daera/Key%20Statistics%20for%202018.pdf" ext-link-type="uri">https://www.daera-ni.gov.uk/sites/default/files/publications/daera/Key%20Statistics%20for%202018.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2019-03-22">(accessed on 22 March 2019)</date-in-citation></element-citation></ref><ref id="B189-vaccines-09-01403"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Step</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Woolums</surname><given-names>A.R.</given-names></name></person-group><article-title>Bovine Respiratory Disease Looking Back and Looking Forward, What Do We See?</article-title><source>Veter. Clin. Food Anim.</source><year>2020</year><volume>36</volume><fpage>239</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1016/j.cvfa.2020.03.009</pub-id><pub-id pub-id-type="pmid">32451026</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-09-01403-f001" orientation="portrait"><label>Figure 1</label><caption><p>Vaccine antigen type consequence on vaccine safety and immunogenicity.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-01403-g001.jpg"/></fig><table-wrap position="float" id="vaccines-09-01403-t001" orientation="portrait"><object-id pub-id-type="pii">vaccines-09-01403-t001_Table 1</object-id><label>Table 1</label><caption><p>Common viral and bacterial pathogens implicated in BRDC.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Viruses</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Bacteria</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mycoplasma spp.</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bovine herpesvirus-1 (BHV-1)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Mannheimia (Pasteurella) haemolytica</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Mycoplasma bovis</italic>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bovine respiratory syncytial virus (BRSV)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Pasteurella multocida</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">Ureaplasma</italic> spp.</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bovine viral diarrhoea virus (BVDV)</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">Histophilus (Haemophilus) somni</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bovine parainfluenza virus type-3 (BPIV-3)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Bovine adenovirus (BAV)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bovine coronavirus (BCoV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vaccines-09-01403-t002" orientation="portrait"><object-id pub-id-type="pii">vaccines-09-01403-t002_Table 2</object-id><label>Table 2</label><caption><p>Main advantages and disadvantages of intranasal vaccination in cattle.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">
<bold>Advantages</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">More neutral pH and lower levels of enzymatic activity than digestive tract</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Prime neonatal calf in the presence of MDA</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Needle-free/non-invasive</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Induction of systemic and mucosal immunity</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">User-friendly (potential use in herds/developing world/remote farms)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>Disadvantages</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rapid clearance of low affinity antigens</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Potential antigen loss during inoculation (impact on cost)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Inefficient uptake</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lack of compatible adjuvants for mucosal vaccines</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>